Fluorophenyl beta-hydroxyethylamine and use thereof in treatment of hyperglycemia

By developing fluorine-substituted β-hydroxyethylamine compounds to activate β2-adrenergic receptors, the side effects of insulin-dependent therapy in existing technologies have been resolved, achieving effective blood glucose reduction without increasing cardiovascular risk.

CN118930444APending Publication Date: 2024-11-12ATROGI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311759174.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-09-13
Filing Date
2018-09-13
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the treatment of hyperglycemia and type 2 diabetes, common insulin-dependent methods have side effects, and there are insufficient non-insulin-dependent treatments that are difficult to effectively activate β2-adrenergic receptors to promote glucose uptake without causing cardiovascular risks.

Method used

A class of fluorinated β-hydroxyethylamine compounds were developed as β2-adrenergic receptor agonists that can increase glucose uptake in skeletal muscle without significant cAMP release, thus reducing the side effects of traditional β2-adrenergic agonists.

Benefits of technology

These compounds can effectively promote glucose uptake, lower blood sugar levels, and reduce cardiovascular side effects, providing a new approach to treating hyperglycemia and type 2 diabetes without traditional side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930444A_ABST
    Figure CN118930444A_ABST
Patent Text Reader

Abstract

Provided herein is a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein n, m, X, R1, R2 and R3 have the definitions provided in the specification. The compounds of the present invention can be used for the treatment of hyperglycemia and diseases characterized by hyperglycemia. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application date of September 13, 2018, application number 201880063906.4, and invention name “Fluorophenyl β-hydroxyethylamine and its use in the treatment of hyperglycemia”. Technical Field

[0002] The present invention relates to novel compounds and compositions, and their use in treating hyperglycemia and diseases characterized by hyperglycemia, such as type 2 diabetes. Specifically, the present invention relates to novel compounds, compositions, and methods for treating conditions, such as type 2 diabetes, by activating β2-adrenergic receptors. Importantly, such compounds are believed to have beneficial side effects because the compounds do not exert their effects through significant cAMP release. Background Art

[0003] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an admission that the document is part of the state of the art or is common general knowledge.

[0004] Hyperglycemia or high blood sugar is a condition in which excess glucose circulates in the blood plasma. If left untreated, hyperglycemia can be a serious problem that can develop into life-threatening conditions (such as ketoacidosis). For example, chronic hyperglycemia can cause heart damage in subjects without coronary heart disease or a history of heart failure, and is closely associated with heart attacks and death. Hyperglycemia has a variety of causes, including diabetes and severe insulin resistance.

[0005] Severe insulin resistance (SIR) is a condition in which the patient has a very low level of response to insulin (in extreme cases, no significant response). There are several syndromes characterized by SIR, including Rabson-Mendenhall syndrome, Donohue syndrome (dwarfism), insulin resistance syndrome types A and B, HAIR-AN (hyperandrogenism, insulin resistance, and acanthosis nigricans) syndrome, pseudoacromegaly, and lipodystrophy. Most of these conditions have genetic causes, such as mutations in the insulin receptor gene. The reported prevalence of Donohue syndrome, Rabson-Mendenhall syndrome, and insulin resistance syndrome type A ranges from approximately 50 to 1 in 100,000 cases. However, because some of the conditions are very serious and extremely rare, it is likely that many patients are not diagnosed before they die, especially in less developed areas of the world. Therefore, it is difficult to estimate the exact number of patients with these syndromes.

[0006] The current standard of care for hyperglycemia in SIR patients is a controlled diet supplemented with medications that affect insulin receptor sensitivity, such as metformin or insulin supplements. However, particularly for diseases caused by mutations in the insulin receptor gene, this treatment has been poorly effective and has ultimately proven unsuccessful.

[0007] Diabetes mellitus includes two distinct diseases, type 1 (or insulin-dependent diabetes) and type 2 (insulin-independent diabetes), both of which involve disturbances in glucose homeostasis. Type 2 diabetes affects more than 400 million people worldwide, and this number is rising rapidly. Complications of type 2 diabetes include serious cardiovascular problems, renal failure, peripheral neuropathy, blindness, and even loss of limbs and ultimately death in the advanced stages of the disease. Type 2 diabetes is characterized by insulin resistance in skeletal muscle and adipose tissue, and there is currently no definitive cure. Most of the treatments used today focus on remediating dysfunctional insulin signaling or inhibiting glucose output from the liver, but many of these treatments have some disadvantages and side effects. Therefore, there is great interest in identifying new non-insulin-dependent ways to treat type 2 diabetes.

[0008] In type 2 diabetes, the insulin signaling pathway is blunted in peripheral tissues such as adipose tissue and skeletal muscle. Methods for treating type 2 diabetes typically include lifestyle changes, as well as insulin injections or oral medications to regulate glucose homeostasis. Type 2 diabetes patients in the late stages of the disease develop "β-cell failure," an inability of the pancreas to release insulin in response to high blood sugar levels. In the late stages of the disease, patients typically require insulin injections combined with oral medications to control their diabetes. In addition, most common drugs have side effects, including downregulation or desensitization of the insulin pathway and / or promotion of lipid incorporation in adipose tissue, liver, and skeletal muscle. Therefore, it is highly desirable to identify new methods for treating metabolic diseases such as type 2 diabetes that do not include these side effects.

[0009] After a meal, elevated blood glucose levels stimulate the release of insulin from the pancreas. Insulin mediates the normalization of blood glucose levels. Insulin's important role in glucose metabolism includes promoting glucose uptake into skeletal muscle and adipocytes and increasing glycogen storage in the liver. In the fed state, skeletal muscle and adipocytes are responsible for insulin-mediated glucose uptake and utilization, making them important sites of glucose metabolism.

[0010] The signaling pathways downstream of the insulin receptor have been elusive. Briefly, the control of glucose uptake by insulin involves activation of the insulin receptor (IR), insulin receptor substrates (IRS), phosphoinositide 3-kinase (PI3K), which in turn stimulates phosphatidylinositol (3,4,5)-triphosphate (PIP3), mammalian target of rapamycin (also known as mechanistic target of rapamycin, mTOR), Akt / PKB (Akt), and TBC1D4 (AS160), leading to translocation of glucose transporter 4 (GLUT4) to the plasma membrane. Akt activation is thought to be necessary for GLUT4 translocation.

[0011] It should be noted that skeletal muscle is a major component of mammalian body weight and plays a vital role in regulating systemic glucose metabolism, being responsible for 85% of the total body glucose disposal. Glucose uptake in skeletal muscle is regulated by several intracellular and extracellular signals. Insulin is the most studied mediator, but other mediators also exist. For example, AMP-activated kinase (AMPK) acts as an energy sensor in cells, which can increase glucose uptake and fatty acid oxidation. Since skeletal muscle has a great influence on glucose homeostasis, there may be other mechanisms. In view of the increased prevalence of type 2 diabetes, finding and characterizing novel insulin-independent mechanisms to increase glucose uptake in muscle cells has attracted much attention.

[0012] Blood glucose levels can be regulated by both insulin and catecholamines, but they are released in the body in response to different stimuli. Insulin is released in response to increases in blood glucose levels (e.g., after a meal), while adrenaline and norepinephrine are released in response to various internal and external stimuli (e.g., exercise, emotions, and stress), and also serve to maintain homeostasis of tissues. Insulin is an anabolic hormone that stimulates many growth-related processes, including the uptake of glucose, the formation of glycogen and triglycerides, while catecholamines are primarily catabolic.

[0013] Although insulin and catecholamines generally have opposing effects, they have been shown to have similar effects on glucose uptake in skeletal muscle (Nevzorov et al., Br. J. Pharmacol, 137, 9, (2002)). Specifically, catecholamines are reported to stimulate glucose uptake via adrenergic receptors (Nevzorova et al., Br. J. Pharmacol, 147, 446, (2006); Hutchinson, Bengtsson, Endocrinology, 146, 901, (2005)), thereby providing energy-rich substrates for muscle cells. Thus, in mammals (including humans), the adrenergic and insulin systems can function independently to regulate the energy requirements of skeletal muscle under different circumstances. Since insulin also stimulates many anabolic processes, including some that promote adverse effects (such as stimulating lipid incorporation into tissues leading to, for example, obesity), it would be beneficial to be able to stimulate glucose uptake by other means; for example, by stimulating adrenergic receptors (AR).

[0014] All ARs are G protein-coupled receptors (GPCRs) located on the cell membrane and are characterized by an extracellular N-terminus, followed by seven transmembrane α-helices (TM-1 to TM-7) connected by three intracellular loops (IL-1 to IL-3) and three extracellular loops (EL-1 to EL-3), and finally an intracellular C-terminus. There are three different classes of ARs with different expression patterns and pharmacological properties: α1-, α2-, and β-ARs. α1-ARs include α 1A Subtype, α 1B Isoform and α 1D subtypes, and α2-AR is divided into α 2A , α 2B and α 2C β-AR is also divided into subtypes β1, β2, and β3, of which β2-AR is the major isoform in skeletal muscle cells. AR is a G protein-coupled receptor (GPCR) that can signal through classical secondary messengers such as cyclic adenosine monophosphate (cAMP) and phospholipase C (PLC).

[0015] Many effects occurring in the AR downstream of skeletal muscle are attributed to classical secondary messenger signaling, such as the increase of cAMP level, PLC activity and calcium level. The stimulation related to classical secondary messengers has many effects in different tissues. For example, stimulation can increase the release of glucose in the airflow in heart rate, blood flow, lungs and liver, and if the stimulation of AR should be considered as type 2 diabetes treatment, all of these may be harmful or be considered as harmful side effects. The side effects of classical AR agonists are such as tachycardia, palpitations, tremors, sweating, excitement and increased glucose levels in the blood (exporting glucose from the liver). Therefore, it is possible to activate AR without activating these classical secondary messengers (such as cAMP), so as to increase the glucose uptake in peripheral tissues without stimulating harmful side effects, which will be beneficial.

[0016] Mainly stimulate glucose uptake by mediating the facilitatory glucose transporter (GLUT) of most cells to uptake glucose. GLUT is a transporter that mediates the transport of glucose and / or fructose on the plasma membrane on a concentration gradient. The GLUT family has fourteen known members, named GLUT1-14, which are divided into three categories (Class I, Class II and Class III) according to their substrate specificity and tissue expression. GLUT1 and GLUT4 are the most studied isoforms, belonging to Class I together with GLUT2 and GLUT3, and Class I mainly transports glucose (Class II also transports fructose by comparison). GLUT1 is widely expressed and is responsible for the transport of basal glucose. GLUT4 is only expressed in peripheral tissues (such as skeletal muscle, myocardium) and adipose tissue. It has also been reported that GLUT4 is expressed in, for example, the brain, kidney and liver. GLUT4 is the main isoform involved in the glucose uptake stimulated by insulin. The mechanism that insulin signaling increases glucose uptake is mainly transferred from intracellular storage to the plasma membrane by GLUT4. It is known that GLUT4 translocation is induced by stimulation of β2-adrenergic receptors.

[0017] Therefore, a possible treatment for disorders involving dysregulated glucose homeostasis or glucose uptake in mammals, such as type 2 diabetes, would involve activation of the β2-adrenergic receptor, thereby causing GLUT4 to translocate to the plasma membrane and promote glucose uptake in skeletal muscle, thereby leading to normalization of systemic glucose homeostasis. In addition, it would be advantageous if the treatment did not involve signaling through cAMP, as this would result in beneficial side effects.

[0018] The vasodilator 4-(2-(butylamino)-1-hydroxyethyl)phenol, which has been used to treat peripheral vascular disease, has been found to initially increase blood glucose and has been contraindicated in diabetes and prediabetes (see Unger, H., Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete, 16, 742 (1961)). DETAILED DESCRIPTION

[0019] We have now surprisingly found that certain fluorine-substituted β-hydroxyethylamines acting as agonists at β2-adrenergic receptors increase glucose uptake in skeletal muscle.

[0020] Additionally, we have found that this effect is not mediated by significant cAMP release, thus reducing many of the commonly described side effects (eg, tachycardia, palpitations, tremors, sweating, agitation, etc.) common with traditional β2-adrenergic agonists.

[0021] The use of such compounds in medicine represents a promising strategy for treating diseases characterized by high blood sugar levels (ie, hyperglycemia), such as type 2 diabetes.

[0022] Compounds of the present invention

[0023] In the first aspect of the present invention, there is provided a compound of formula I

[0024]

[0025] or a pharmaceutically acceptable salt thereof, wherein:

[0026] R 1 represents a C optionally substituted by one or more halogen groups 4-12 alkyl;

[0027] R 2 and R 3 Each independently represents H or C optionally substituted by one or more halogen groups 1-3 alkyl;

[0028] or R 2 and R 3 may be joined together to form, together with the carbon atoms to which they are attached, a 3- to 6-membered ring, said ring being optionally substituted with one or more groups independently selected from halo and C1 alkyl optionally substituted with one or more halo;

[0029] Each X independently represents Cl, Br, R a 、-CN、-N3、-N(Rb )R c 、-NO2、-ONO2、-OR d 、-S(O) p R e or -S(O) q N(R f )R g ;

[0030] R a represents C optionally substituted by one or more groups independently selected from G 1-6 alkyl;

[0031] Each R b , R c , R d , R e , R f and R g independently represents H or C optionally substituted by one or more groups independently selected from G 1-6 alkyl;

[0032] Or alternatively, R b and R c and / or R f and R g Any of the may be linked together to form a 4- to 6-membered ring together with the nitrogen atom to which it is attached, the ring optionally containing one additional heteroatom, and the ring optionally consisting of C independently selected from halo, optionally substituted with one or more halo 1-3 Alkyl and =O substituted with one or more groups;

[0033] G represents halogen, -CN, -N(R a1 )R b1 、-OR c1 、-S(O) p R d1 、-S(O) q N(R e1 )R f1 or =O;

[0034] Each R a1 , R b1 , R c1 , R d1 , R e1 and R f1 independently represents H or C optionally substituted by one or more halogen groups 1-6 alkyl;

[0035] Or alternatively, R a1 and R b1 and / or R e1 and Rf1 Any of the may be linked together to form a 4- to 6-membered ring together with the nitrogen atom to which it is attached, the ring optionally containing one additional heteroatom, and the ring optionally consisting of C independently selected from halo, optionally substituted with one or more halo 1-3 Alkyl and =O substituted with one or more groups;

[0036] m represents 1 to 5;

[0037] n represents 0 to 4;

[0038] The condition is that the sum of m and n is equal to or less than 5;

[0039] Each p independently represents 0, 1, or 2; and

[0040] Each q independently represents 1 or 2;

[0041] Such compounds (including pharmaceutically acceptable salts) may be referred to herein as "compounds of the invention".

[0042] For the avoidance of doubt, the skilled person will understand that references herein to compounds of a particular aspect of the invention (such as the first aspect of the invention, e.g. compounds of formula I) will include references to all embodiments and specific features thereof, which embodiments and specific features may be combined to form further embodiments.

[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0044] Pharmaceutically acceptable salts include acid addition salts and base addition salts. Such salts can be formed by conventional means, for example, by reacting the compound of the present invention in free acid or free base form with one or more equivalents of appropriate acid or base, optionally in a solvent or salt-insoluble culture medium, and then removing the solvent or the culture medium using standard techniques (e.g., in a vacuum, by freeze drying or by filtering) to form such salts. Salts can also be prepared by, for example, exchanging the counter ions of the compound of the present invention in salt form with another counter ion using a suitable ion exchange resin.

[0045] Specific acid addition salts that may be mentioned include carboxylates (e.g. formates, acetates, trifluoroacetates, propionates, isobutyrates, heptanoates, decanoates, caprylates, stearates, acrylates, caproates, propionates, ascorbates, citrates, glucuronates, glutamates, glycolates, α-hydroxybutyrates, lactates, tartrates, phenylacetates, mandelates, phenylpropionates, phenylbutyrates, benzoates, chlorobenzoates, methylbenzoates, hydroxybenzoates, methoxybenzoates, dinitrobenzoates, o-acetoxybenzoates, salicylates, nicotinates, isonicotinates, cinnamates, oxalates, malonates, , succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, hippurate, phthalate or terephthalate), a halide salt (such as a chloride salt, a bromide salt or an iodide salt), a sulfonate (such as a benzenesulfonate, a methyl-benzenesulfonate, a bromo-benzenesulfonate or a chloro-benzenesulfonate, a xylenesulfonate, a methanesulfonate, an ethanesulfonate, a propanesulfonate, a hydroxyethanesulfonate, a 1- or 2-naphthalenesulfonate or a 1,5-naphthalenedisulfonate) or a sulfate, a pyrosulfate, a bisulfite, a sulfite, a bisulfite, a phosphate, a monohydrogenphosphate, a dihydrogenphosphate, a metaphosphate, a pyrophosphate or a nitrate, etc.

[0046] Specific base addition salts that may be mentioned include salts formed with alkali metals such as Na and K salts, alkaline earth metals such as Mg and Ca salts, organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine and lysine, and inorganic bases such as ammonia and aluminum hydroxide. More specifically, base addition salts that may be mentioned include Mg salts, Ca salts, and most particularly, K and Na salts.

[0047] For the avoidance of doubt, the compound of the first aspect of the present invention can exist in solid form, and therefore the scope of the present invention includes all amorphous forms, crystalline forms and partially crystalline forms thereof, and can also exist in oily form. When the compound of the first aspect of the present invention exists in crystalline form and partially crystalline form, such form can include solvates, which are included in the scope of the present invention. The compound of the first aspect of the present invention can also exist in solution form.

[0048] The compounds of the first aspect of the invention may contain double bonds and may therefore exist as E (hetero) and Z (same) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the present invention.

[0049] The compounds of the first aspect of the present invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the present invention.

[0050] The compound of the first aspect of the present invention may also contain one or more asymmetric carbon atoms, and therefore may exhibit optical activity and / or diastereoisomerism. Conventional techniques (such as chromatography or fractional crystallization) may be used to separate diastereoisomers. Various stereoisomers (i.e. enantiomers) may be isolated by using conventional techniques (such as fractional crystallization or HPLC) to separate other mixtures of racemic or compound. Alternatively, the desired optical isomers (i.e. "chiral pool" method) may be obtained from appropriate optically active starting materials under conditions that do not cause racemization or epimerization by reacting appropriate starting materials with "chiral auxiliary agents", and the chiral auxiliary agents may be subsequently removed by derivatization (i.e., resolution, including dynamic resolution) at appropriate stages; for example, under conditions known to technicians, with pure chiral acid, then by conventional methods such as chromatography, or by reacting with suitable chiral reagents or chiral catalysts, diastereoisomer derivatives may be separated. All stereoisomers and mixtures thereof are included within the scope of the present invention.

[0051] As used herein, references to halo and / or halogen groups will each independently refer to fluorine, chlorine, bromine, and iodine (eg, fluorine (F) and chlorine (Cl)).

[0052] Unless otherwise specified, C as defined herein 1-z Alkyl groups (where z is the upper limit of the range) may be straight chain or, when there are a sufficient number (ie, a minimum of three) of carbon atoms, may be branched and / or cyclic (thus forming a C 3-z When there are a sufficient number of carbon atoms (i.e., at least four), such groups may also be partially cyclic. Partially cyclic alkyl groups that may be mentioned include cyclopropylmethyl and cyclohexylethyl. When there are a sufficient number of carbon atoms, such groups may also be polycyclic (e.g., bicyclic or tricyclic) or spirocyclic. Such alkyl groups may also be saturated, or when there are a sufficient number of carbon atoms (i.e., at least two), they may be unsaturated (e.g., forming a C 2-z Alkenyl or C 2-z Specific alkyl groups that may be mentioned include saturated alkyl groups.

[0053] For the avoidance of doubt, as used herein, references to heteroatoms will take on the normal meaning as understood by those skilled in the art. Specific heteroatoms that may be mentioned include phosphorus, selenium, tellurium, silicon, boron, oxygen, nitrogen and sulfur (e.g. oxygen, nitrogen and sulfur).

[0054] For the avoidance of doubt, reference to a polycyclic (e.g. bicyclic or tricyclic) group (e.g. when used in the context of a cycloalkyl group) refers to a ring system where at least two breaks are required to convert such rings into a straight chain, the minimum number of such breaks corresponding to the number of rings defined (e.g. the term bicyclic may mean that a minimum of two breaks are required to convert the rings into a straight chain). For the avoidance of doubt, the term bicyclic (e.g. when used in the context of an alkyl group) may refer to a group where the second ring of the bicyclic system is formed between two adjacent atoms of the first ring, and may also refer to a group where two non-adjacent atoms are linked via an alkylene group, the latter group being referred to as bridged.

[0055] The present invention also encompasses isotopically labeled compounds of the present invention, which are identical to the compounds described herein, except that one or more atoms are replaced by atoms having an atomic mass or mass number different from the mass or mass number of atoms typically found in nature (or found most abundantly in nature). It is contemplated that all isotopes of any specific atom or element described herein are within the scope of the compounds of the present invention. Thus, the compounds of the present invention also include deuterated compounds, i.e., where one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.

[0056] For the avoidance of doubt, where the identities of two or more substituents in the compounds of the invention may be the same, the actual identities of the individual substituents are not in any way interdependent. For example, where two or more X groups are present, the X groups may be the same or different. Similarly, where two or more X groups are present and each X group represents a halo, the halo groups in question may be the same or different. Likewise, where more than one R is present, the a and each independently represents a C substituted by one or more G groups 1-6 When the moiety is alkyl, the identity of each G is in no way interdependent.

[0057] The skilled artisan will appreciate that the compounds of the invention that are the subject of the present invention include stable compounds. That is, the compounds of the invention include compounds that are sufficiently robust to survive isolation, for example, from a reaction mixture to a useful degree of purity.

[0058] All embodiments of the present invention and the specific features mentioned herein may be used alone or in combination with any other embodiments and / or specific features mentioned herein (thus describing more specific embodiments and specific features as disclosed herein) without departing from the disclosure of the present invention.

[0059] In a specific embodiment of the first aspect of the present invention, R 1 represents a C optionally substituted by one or more halogen groups 4-10 Alkyl, such as C4-8 alkyl.

[0060] In a specific embodiment of the first aspect of the present invention, R 1 represents C optionally substituted by one or more F 4-10 Alkyl, such as C optionally substituted with one or more F 4-8 alkyl.

[0061] In a more specific embodiment, R 1 Represents C 4-10 Alkyl, such as C 4-8 alkyl.

[0062] In another embodiment, R 1 Represents C 4-7 Alkyl (e.g. C 4-5 For example, R 1 It may represent a C4 alkyl group (eg, a linear C4 alkyl group) or a C5 alkyl group (eg, a branched C5 alkyl group).

[0063] In certain embodiments, wherein R 1 Represents C 4-12 Alkyl (e.g. C 4-7 Alkyl, such as C 4-5 alkyl), the carbon bonded to the required -NH- group is unbranched, for example, represented by a -CH2- moiety.

[0064] In certain embodiments, wherein R 1 Represents C 4-12 Alkyl (e.g. C 4-7 Alkyl, such as C 4-5 alkyl), the carbon bonded to the required -NH- group is branched, for example, as represented by a -CH(CH3)- moiety.

[0065] Specific R that can be mentioned 1 The group contains an alkyl group (e.g. 4-10 Alkyl, such as C 4-8 Alkyl) is a straight-chain group (eg, n-butyl, n-hexyl or n-octyl).

[0066] Some additional R that may be mentioned 1 The group contains an alkyl group (e.g. 4-10 Alkyl, such as C 4-8 Alkyl, or especially C 4-6 The alkyl group is a straight-chain group (e.g., n-butyl, n-hexyl or n-octyl, such as n-butyl), the alkyl group is a branched group (e.g., tert-butyl, neopentyl or 2-methylpentyl) or the alkyl group is a cyclic / partial cyclic group (e.g., methylcyclobutyl or methylcyclopropyl).

[0067] More specific R1 The group contains alkyl groups representing C 4-12 Alkyl (e.g. C 4-7 Alkyl, such as C 4-5 alkyl) radical, wherein the carbon bonded to the required -NH- radical is substituted by a substituent, for example by -CH(R 4 )-part indicates that R 4 Represents C 1-2 Alkyl (eg, methyl), for example, wherein R 1 It represents 2-pentyl.

[0068] In certain embodiments, R 1 represents n-butyl, tert-butyl or 2-pentyl.

[0069] In certain embodiments, R 1 It represents 2-pentyl.

[0070] In another embodiment that may be mentioned, R 1 represents n-butyl, tert-butyl, 2-pentyl, 2-methyl-pent-2-yl, 1-methylcyclobutyl, 1-methylcyclopropyl or neopentyl.

[0071] In a specific embodiment, R 1 It does not represent tert-butyl.

[0072] For the avoidance of doubt, in certain embodiments, R 1 It represents tert-butyl.

[0073] In a specific embodiment, R 1 Represents a group of structures (i.e. substructures)

[0074]

[0075] in:

[0076] R x , R y and R z Each independently represents H or C optionally substituted by one or more F 1-11 Alkyl (e.g. C1 alkyl);

[0077] Or alternatively, R x and R z The R and R may be linked together to form, together with the carbon atoms to which they are attached, a 4 to 6 membered ring, which is optionally substituted with one or more Fs.

[0078] As used herein, the skilled person will understand that The terminal bond represents the point of attachment (eg, to the required N atom in the compounds of Formula I including all embodiments thereof).

[0079] For the avoidance of doubt, the skilled person will understand that in R 1 By with R x Group, R y Group and R z In the case of a substructure of a group, R x Group, R y Group and R z The sum of the carbon atoms present in the group, and the sum of the carbon atoms to which it is attached, may not exceed the sum of the carbon atoms of the corresponding R 1 The sum of the carbons present in a group is as defined herein (including all embodiments thereof).

[0080] For the avoidance of doubt, the form represents R 1 A group that is part of the structure (e.g. R x , R y and R z and the carbon to which it is attached) can be as described herein for R 1 is optionally substituted as defined.

[0081] In another specific embodiment, R 1 Can be expressed

[0082]

[0083] Where R x , R y and R z Each independently represents H or C as appropriate 1-11 alkyl.

[0084] In a more specific embodiment, R 1 Can be expressed

[0085]

[0086] Where R x and R z Each independently represents H or C as appropriate 1-11 In a specific embodiment, when R x and R z When it is not H, the two can be the same.

[0087] In an alternative embodiment, when R x and R z When not H, the two can be different (for example, R x It can be propyl and R z is a methyl group, i.e. R 1 may be 2-pentyl).

[0088] In this case, the skilled person will recognize that R x and Rz The corresponding carbon is a stereocenter, and therefore R 1 can be described as

[0089]

[0090] The skilled person will understand that, depending on R x or R z Such stereocenters may be referred to as being in the (R) configuration or the (S) configuration, whether assigned a higher priority (according to the Cahn-Ingold-Prelog system as understood by those skilled in the art).

[0091] In specific such embodiments, R x and R z Can be expressed independently of C 1-11 Alkyl, where R x is higher than R z A larger alkyl group (i.e., a larger number of carbon atoms forming the alkyl group) is present. For example, in such embodiments, R z Can represent C 1-2 Alkyl, and R x Can represent C 3-10 alkyl.

[0092] In specific such embodiments, R 1 is a set of structures

[0093]

[0094] If R z Can represent C 1-2 Alkyl, and R x Can represent C 3-8 alkyl.

[0095] In specific such embodiments:

[0096] R z represents a methyl group; and / or (for example, and)

[0097] R x It represents n-propyl.

[0098] In an alternative such embodiment, R 1 is a set of structures

[0099]

[0100] If R z Can represent C 1-2 Alkyl, and R x Can represent C 3-8 alkyl.

[0101] In specific such alternative embodiments:

[0102] R z represents a methyl group; and / or (for example, and)

[0103] R x It represents n-propyl.

[0104] In another alternative embodiment, R 1 Can be expressed

[0105]

[0106] Where R x Indicates H or C 3-9 Alkyl, such as n-propyl (i.e. R 1 may be n-butyl).

[0107] The skilled artisan will appreciate that the prefixes "n-", "sec-", and "tert-" represent the terms "normal", "secondary", and "tertiary" when applied to alkyl groups. The term "normal" refers to a linear alkyl group in which the point of attachment of the group to the rest of the molecule is through the carbon atom at the end of the carbon chain, and thus the carbon atom is bonded to another carbon atom. The term "secondary" refers to the point of attachment of the rest of the molecule to the alkyl group through the carbon atom adjacent to the end of the carbon chain, and thus the carbon itself is bonded to two other carbon atoms. The term "tertiary" refers to the point of attachment of the alkyl group to the rest of the molecule through a carbon atom that is bonded to three other carbon atoms.

[0108] In a specific embodiment of the first aspect of the present invention, each R 2 and R 3 Independently represents H or C 1-2 Alkyl (eg, methyl).

[0109] In a further embodiment of the first aspect of the invention, each R 2 and R 3 and independently represent H, methyl or ethyl (eg, methyl).

[0110] In a more specific embodiment, R 2 Indicates H and R 3 It represents H or methyl.

[0111] In yet more specific embodiments, R 2 and R 3 Each represents H.

[0112] In certain embodiments of the compounds of the present invention, m represents 1, 2 or 3. For example, m may represent 1 or 2.

[0113] In certain embodiments of the compounds of the present invention, when m represents 3, the F atom is located at the 2-position, 3-position and 4-position or the 3-position, 4-position and 5-position.

[0114] In certain embodiments of the compounds of the present invention, when m represents 2, the F atoms are positioned at the 2-position and the 4-position, or the 3-position and the 4-position, or the 3-position and the 5-position (eg, the 3-position and the 4-position).

[0115] In further embodiments, when m represents 2, the F atoms are positioned at the 2-position and the 3-position, the 2-position and the 4-position, or the 3-position and the 4-position, or the 3-position and the 5-position.

[0116] In certain embodiments of the compounds of the present invention, when m represents 1, the F atom is located at the 3-position or the 4-position (eg, the 3-position).

[0117] For example, the skilled artisan will appreciate that in certain embodiments, when m represents 2, the F atom is positioned at the 3- and 4-positions, and when m represents 1, the F atom is positioned at the 3- or 4-position (eg, the 3-position).

[0118] In further embodiments, when m represents 1, the F atom is located at the 2-position, 3-position, or 4-position (eg, 3-position).

[0119] In certain embodiments of the compounds of the present invention, wherein n represents 0, 1, 2 or 3, each X independently represents Cl, Br, R a 、-CN、-N3、-N(R b )R c , -NO2 or -OR d , where R a represents C optionally substituted by one or more F 1-4 alkyl, and wherein R b , R c and R d Each independently represents H or C optionally substituted by one or more F 1-4 alkyl.

[0120] For example, each X can independently represent Cl, Br, R a 、-CN、-N3、-N(R b )R c , -NO2 or OR d , where R a represents C optionally substituted by one or more F 1-4 Alkyl, and R b , R c and R d Each independently represents H or C optionally substituted by one or more F or =O 1-4 alkyl.

[0121] In other embodiments, each X can independently represent Cl, Br, R a 、-CN、-N3、-N(R b )R c , -NO2 or OR d , where R a represents C optionally substituted by one or more F 1-4 Alkyl, and R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl, and R d represents H or C optionally substituted by one or more F 1-4 alkyl.

[0122] In more specific embodiments, each X independently represents Cl, R a 、-N(R b )R c , -CN or -OH, where R a represents C optionally substituted by one or more F 1-4 Alkyl (e.g. C 1-2 Alkyl) (e.g., R a represents -CH3, -CHF2 or -CF3 (e.g. -CF3)), and R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl (e.g., R c represents -C(O)CH3).

[0123] In yet more specific embodiments, each X independently represents Cl, R a 、-N(R b )R c or -OH, where R a represents C optionally substituted by one or more F 1-2 Alkyl (e.g., R a represents -CHF2 or -CF3 (e.g. -CF3)), and R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl (e.g., R c represents -C(O)CH3).

[0124] In another specific embodiment, each X independently represents Cl, R a , -NH2, -NHC(O)CH3, -CF3 or -OH, where R arepresents C optionally substituted by one or more F 1-2 alkyl.

[0125] In yet other specific embodiments, each X independently represents Cl, -NH2, -NHC (O) CH3, -CF3 or -OH. In other embodiments, each X independently represents -NH2, -NHC (O) CH3 or -OH, such as -NH2 or -NHC (O) CH3 (e.g. -NH2).

[0126] In some embodiments of the compounds of the invention, n represents 0, 1 or 2 (eg, 1 or 2, eg, 1).

[0127] In certain embodiments of the compounds of the invention, n represents 0, 1 or 2 (eg, 0 or 1).

[0128] In a particular embodiment of the compounds of the present invention, n represents 1.

[0129] In an alternative embodiment of the compounds of the invention, n represents zero.

[0130] In certain embodiments, wherein n represents 2, each X independently represents Cl, -NH2, -NHC(O)CH3, -CF3, or -OH. In certain other embodiments, wherein n represents 2, each X independently represents -NH2, -NHC(O)CH3, or -OH. In such embodiments, the X groups may be positioned at the 2- and 3-positions, or the 2- and 4-positions, or the 3- and 5-positions (e.g., the 2- and 3-positions) of the required phenyl ring.

[0131] In certain embodiments, wherein n represents 1, X represents Cl, R a , -NH2, -NHC(O)CH3 or -OH, where R a represents C optionally substituted by one or more F 1-2 In certain other embodiments, wherein n represents 1, X represents Cl, -NH, -NHC(O)CH or -OH. In specific embodiments, wherein n represents 1, X represents -NH, -NHC(O)CH or -OH. In such embodiments, the X group may be positioned at the 3-, 4- or 5-position of the required benzene ring. In other such embodiments, the X group may also (or alternatively) be positioned at the 2-position of the required benzene ring.

[0132] In certain embodiments, wherein n represents 1, X represents -NH2 or -NHC(O)CH3 (e.g., -NH2). In such embodiments, the X group may be positioned at the 3-position or 4-position of the required benzene ring. In other such embodiments, the X group may be positioned at the 2-position or 3-position (e.g., two positions) of the required benzene ring.

[0133] In certain embodiments, wherein n represents 1, X represents -OH. In such embodiments, the X group can be positioned at the 3-position, 4-position or 5-position of the required benzene ring. In other such embodiments, the X group can be positioned at the 2-position or 3-position (e.g., two positions) of the required benzene ring.

[0134] In certain embodiments that may be mentioned, when n represents 2 or more (ie, more than one X substituent is present), no more than one X may represent a substituent selected from -N(R b )R c AND-OR d A group (especially where R b , R c and R d Indicates H).

[0135] In further embodiments:

[0136] m represents 1 or 2 (e.g., 1);

[0137] n represents 1;

[0138] X represents -NH2, -NHC(O)CH3 or -OH;

[0139] In particular, wherein the F atom is located at the 2-position, 3-position, 4-position or 5-position of the essential benzene ring; and

[0140] In particular, the X groups are located at the 3-position, 4-position and 5-position of the essential benzene ring.

[0141] In a specific embodiment that may be mentioned, the sum of m and n does not exceed 2.

[0142] In another embodiment, a compound of formula I or a pharmaceutically acceptable salt thereof is provided, wherein the essential phenyl ring is unsubstituted at the 2-position, 3-position, 5-position and 6-position. For example, in certain embodiments, the essential phenyl ring is unsubstituted at the 5-position and 6-position.

[0143] In a specific embodiment of the first aspect of the present invention:

[0144] m represents 1;

[0145] The F atom is located at the 3-position or 4-position (e.g., the 3-position) of the essential benzene ring; and

[0146] n represents 0.

[0147] In a specific embodiment of the first aspect of the present invention:

[0148] m represents 1;

[0149] The F atom is located at the 3-position of the essential benzene ring; and

[0150] n represents 1;

[0151] X represents -NH2, -NHC(O)CH3 or -OH; and

[0152] The X group is positioned at the 4-position or 5-position of the essential benzene ring.

[0153] In a specific embodiment of the first aspect of the present invention:

[0154] m represents 1;

[0155] The F atom is located at the 4-position of the essential benzene ring; and

[0156] n represents 1;

[0157] X represents -NH2, -NHC(O)CH3 or -OH; and

[0158] The X group is positioned at the 3-position of the essential benzene ring.

[0159] In a specific embodiment of the first aspect of the present invention:

[0160] m means 2;

[0161] The F atoms are located at the 3- and 5-positions of the essential benzene rings; and

[0162] n represents 0.

[0163] In a specific embodiment of the first aspect of the present invention:

[0164] m means 2;

[0165] The F atoms are located at the 3- and 4-positions of the essential benzene rings; and

[0166] n represents 0.

[0167] In a specific embodiment of the first aspect of the present invention:

[0168] m means 2;

[0169] The F atoms are located at the 2- and 4-positions of the essential benzene ring;

[0170] n represents 1;

[0171] X represents -NH2, -NHC(O)CH3 or -OH; and

[0172] The X group is positioned at the 3-position of the essential benzene ring.

[0173] For example, in a specific embodiment of the first aspect of the present invention:

[0174] R 1 represents n-butyl;

[0175] R 2 and R 3 Indicates H;

[0176] m represents 1;

[0177] The F atom is located at the 4-position of the essential benzene ring;

[0178] n represents 1; and

[0179] X represents -NH2 and is located at the 3-position on the phenyl group to which it is attached.

[0180] Similarly, in a specific embodiment:

[0181] R 1 represents tert-butyl;

[0182] R 2 and R 3 Indicates H;

[0183] m represents 1; and

[0184] The F atom is located at the 3-position of the essential benzene ring.

[0185] For the avoidance of doubt, when R 1 represents n-butyl, R 2 and R 3 Wherein: represents H, m represents 1, and the F atom is located at the 4-position of the essential benzene ring, and n represents 1, and X represents -NH2 and is located at the 3-position of the essential benzene ring, the compound of formula I may be depicted as:

[0186]

[0187] In another specific embodiment of the compounds of the present invention, the compound of formula I is a compound of formula IA

[0188]

[0189] Where R 1 , R 2 and R 3 As defined herein (including, for the avoidance of doubt, all embodiments thereof), and Y 1 , Y 2 , Y 3 , Y 4 and Y 5 Each independently represents H, F or X, wherein X is as defined herein (including all embodiments thereof for the avoidance of doubt),

[0190] The condition is Y 1To Y 5 At least one of them represents F.

[0191] In certain embodiments, a compound of formula IA is provided, wherein:

[0192] Y 1 and Y 5 each independently represents H or F; and

[0193] Y 2 , Y 3 and Y 4 Each independently represents H, F, R a 、-CN、-N3、-N(R b )R c , -NO2 or -OR d , where R a represents C optionally substituted by one or more F 1-4 alkyl, and wherein R b , R c and R d Each independently represents H or C optionally substituted by one or more F or =O 1-4 alkyl,

[0194] The condition is Y 1 To Y 5 At least one of them represents F.

[0195] In a specific embodiment, a compound of formula IA is provided, wherein Y 1 and Y 3 represents F (for example, where Y 2 represents X, such as -NH2 or -NHC(O)CH3, and Y 4 and Y 5 Indicates H).

[0196] In another embodiment, a compound of formula IA is provided, wherein Y 2 represents F (for example, where Y 3 represents X, such as -NH2, and Y 1 , Y 4 and Y 5 Indicates H, or Y 1 , Y 3 , Y 4 and Y 5 Indicates H).

[0197] In another embodiment, a compound of formula IA is provided, wherein Y 2 , Y 3 , Y 2 and Y 4 or Y 2and Y 3 represents F, and Y 1 To Y 5 The rest of the represents H.

[0198] In certain embodiments, a compound of formula IA is provided, wherein Y 2 or Y 3 One or two of represent a group selected from Cl, F and -OH (e.g. Cl or F, such as F), and Y 1 To Y 5 The rest of the represents H.

[0199] In a specific embodiment:

[0200] Y 1 and Y 5 each represents H or F; and

[0201] Y 2 , Y 3 and Y 4 Each independently represents H, F, R a 、-CN、-N(R b )R c or -OH, where R a represents C optionally substituted by one or more F 1-2 Alkyl (e.g., R a may represent -CH3, -CF3 or -CHF2), and R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl (e.g., R c Can represent -C(O)CH3),

[0202] The condition is Y 1 To Y 5 One or two of them means F.

[0203] In another specific embodiment:

[0204] Y 1 and Y 5 each represents H; and

[0205] Y 2 , Y 3 and Y 4 Each independently represents H, F, -N(R b )R c , -CN or -OH, where R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl (e.g., Rc Can represent -C(O)CH3),

[0206] The condition is Y 2 , Y 3 and Y 4 One or two of them means F.

[0207] In a more specific embodiment,

[0208] Y 1 and Y 5 each independently represents H or F; and

[0209] Y 2 , Y 3 and Y 4 Each independently represents H, F, -NH2, -NHC(O)CH3 or -OH,

[0210] The condition is Y 2 , Y 3 and Y 4 One or two of them means F.

[0211] In an alternative embodiment:

[0212] Y 1 Indicates H or F;

[0213] Y 2 , Y 3 and Y 4 Each independently represents F, R a 、-CN、-N3、-N(R b )R c , -NO2 or -OR d ; where R a represents C optionally substituted by one or more F 1-4 Alkyl, where R b , R c and R d Each independently represents H or C optionally substituted by one or more F or =O 1-4 Alkyl; and

[0214] Y 5 Indicates H,

[0215] The condition is Y 1 To Y 4 One of them represents F.

[0216] In another alternative embodiment,

[0217] Y 1 Indicates H or F;

[0218] Y2 , Y 3 and Y 4 Each independently represents H, F, Cl, -N(R b )R c or -OH, where R b and R c Each independently represents H or C optionally substituted by =O 1-4 alkyl.

[0219] Y 5 Indicates H,

[0220] The condition is Y 1 To Y 4 One of them represents F.

[0221] In a yet more specific embodiment:

[0222] Y 1 Indicates H or F;

[0223] Y 2 , Y 3 and Y 4 each independently represents H, F, -NH2, -NHC(O)CH3 or -OH; and

[0224] Y 5 Indicates H,

[0225] The condition is Y 1 To Y 4 One of them represents F.

[0226] In a yet more specific embodiment:

[0227] Y 1 , Y 2 and Y 5 each represents H; and

[0228] Y 3 and Y 4 Each independently represents H, F, -NH2, -NHC(O)CH3 or -OH, provided that Y 1 To Y 4 One of them represents F.

[0229] In a yet more specific embodiment:

[0230] Y 1 , Y 2 , Y 3 and Y 5 represents H; and

[0231] Y 4 Indicates F.

[0232] In a yet more specific embodiment:

[0233] Y 1 , Y 2 , Y 4 and Y 5 represents H; and

[0234] Y 3 Indicates F.

[0235] In an alternative embodiment:

[0236] Y 1 , Y 3 , Y 4 and Y 5 represents H; and

[0237] Y 2 Indicates F.

[0238] In further alternative embodiments;

[0239] Y 1 and Y 5 Each represents H;

[0240] Y 2 and Y 4 Each independently represents -NH2, -NHC(O)CH3 or -OH, and Y 3 Indicates F.

[0241] In yet more alternative embodiments:

[0242] Y 1 and Y 5 Each represents H;

[0243] Y 2 and Y 4 each independently represents H or F; and

[0244] Y 3 It represents -NH2, -NHC(O)CH3 or -OH.

[0245] In certain embodiments:

[0246] Y 1 and Y 3 each represents F; and

[0247] Y 2 represents -NH2, -NHC(O)CH3; and

[0248] Y 4 and Y 5 Each represents H.

[0249] In certain other embodiments:

[0250] Y 1 , Y 3 and Y 5 represents H; and

[0251] Y 2 and Y 4 Each represents F.

[0252] In certain alternative embodiments:

[0253] Y 1 , Y 4 and Y 5 represents H; and

[0254] Y 2 and Y 3 Each represents F.

[0255] The skilled person will appreciate that specific X groups (and their positions and numbers, such as those corresponding to Y in the compound of formula IA) may be mentioned. 1 To Y 5 Groups) include groups present in the examples provided herein.

[0256] Similarly, the skilled person will appreciate that specific R 1 Group, R 2 Group and R 3 Groups include those present in the examples provided herein.

[0257] For example, in a specific embodiment of the first aspect of the present invention:

[0258] R 1 represents n-butyl or cyclopropanemethyl;

[0259] R 2 and R 3 Indicates H;

[0260] m represents 1;

[0261] n represents 0; and

[0262] The F atom is located at the 4-position on the phenyl group to which it is attached (ie, in the compound of formula IA, Y 1 , Y 2 , Y 4 and Y 5 represents H, and Y 3 Indicates -F).

[0263] In an alternative example of a specific embodiment of the first aspect of the invention:

[0264] R 1represents n-butyl or cyclopropanemethyl;

[0265] R 2 and R 3 Indicates H;

[0266] m represents 1;

[0267] n represents 0; and

[0268] The F atom is located at the 3-position on the phenyl group to which it is attached (ie, in the compound of formula IA, Y 1 , Y 3 , Y 4 and Y 5 represents H, and Y 2 Indicates -F).

[0269] In another example of a specific embodiment of the first aspect of the invention:

[0270] R 1 represents tert-butyl;

[0271] R 2 and R 3 Indicates H;

[0272] m represents 1;

[0273] n represents 0; and

[0274] The F atom is located at the 3-position on the phenyl group to which it is attached (ie, in the compound of formula IA, Y 1 , Y 3 , Y 4 and Y 5 represents H, and Y 2 Indicates -F).

[0275] Specific compounds of the first aspect of the present invention that may be mentioned include the compounds of the examples provided herein and their pharmaceutically acceptable salts. Compounds of formula I that may be mentioned include:

[0276] 2-(Butylamino)-1-(3,5-difluorophenyl)ethan-1-ol

[0277] 2-(Butylamino)-1-(3,4-difluorophenyl)ethan-1-ol

[0278] 1-(4-Amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0279] N-(3-(2-(Butylamino)-1-hydroxyethyl)-2,6-difluorophenyl)acetamide

[0280] 1-(3-Amino-2,4-difluorophenyl)-2-(butylamino)ethan-1-ol

[0281] 1-(4-Amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0282] and pharmaceutically acceptable salts thereof.

[0283] More specific compounds of formula I include:

[0284] 2-(Butylamino)-1-(3,5-difluorophenyl)ethan-1-ol

[0285] 2-(Butylamino)-1-(3,4-difluorophenyl)ethan-1-ol

[0286] and pharmaceutically acceptable salts thereof.

[0287] Certain specific compounds of formula I include:

[0288] 1-(4-Amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0289] N-(3-(2-(Butylamino)-1-hydroxyethyl)-2,6-difluorophenyl)acetamide

[0290] 1-(3-Amino-2,4-difluorophenyl)-2-(butylamino)ethan-1-ol

[0291] 1-(4-Amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0292] and pharmaceutically acceptable salts thereof.

[0293] Some compounds of formula I that may be mentioned include:

[0294] 2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0295] 2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0296] 2-(Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0297] 2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0298] 1-(4-Fluorophenyl)-2-((pentan-2-yl)amino)ethan-1-ol

[0299] and pharmaceutically acceptable salts thereof.

[0300] Additional compounds of formula I that may be mentioned include:

[0301] 1-(3-Fluorophenyl)-2-((2-methylpentan-2-yl)amino)ethan-1-ol

[0302] 2-(tert-Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0303] 2-(Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0304] 2-(tert-Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0305] 2-(Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0306] 2-(2-(tert-Butylamino)-1-hydroxyethyl)-5-fluorophenol

[0307] 2-(2-(Butylamino)-1-hydroxyethyl)-5-fluorophenol

[0308] 1-(3-Fluorophenyl)-2-((1-methylcyclobutyl)amino)ethan-1-ol

[0309] 1-(3-Fluorophenyl)-2-((1-methylcyclopropyl)amino)ethan-1-ol

[0310] 5-(2-(tert-Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0311] 5-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0312] 3-(2-(tert-Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0313] 3-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0314] 1-(3-Amino-2-fluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0315] 1-(3-Amino-2-fluorophenyl)-2-(butylamino)ethan-1-ol

[0316] 1-(3-Fluorophenyl)-2-(neopentylamino)ethan-1-ol

[0317] 1-(3-Fluorophenyl)-2-((1-(trifluoromethyl)cyclopropyl)amino)ethan-1-ol

[0318] 1-(3-Amino-2,4-difluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0319] 2-(tert-Butylamino)-1-(3-fluoro-2-methylphenyl)ethan-1-ol

[0320] and pharmaceutically acceptable salts thereof.

[0321] As described herein, the compounds of the first aspect of the present invention may also contain one or more asymmetric carbon atoms, and therefore may exhibit optical rotation and / or diastereoisomerism. In addition, it has been found that some such optical rotation and / or diastereoisomers may demonstrate increased effectiveness in treating hyperglycemia or diseases characterized by hyperglycemia (such as type 2 diabetes), as described herein.

[0322] As will be appreciated by those skilled in the art, in particular embodiments of the first aspect of the invention, the compound of formula I is such that the carbon substituted with the requisite -OH group is in the (R) configuration.

[0323] Thus, in specific embodiments, the compound of formula I is a compound of formula IB

[0324]

[0325] Where n, X, R 1 , R 2 and R 3 As described herein (ie as described in the first aspect of the invention including all embodiments and specific features and combinations thereof).

[0326] In a specific embodiment, a compound of formula IB is provided, wherein:

[0327] m represents 1;

[0328] n represents 0;

[0329] R 1 Represents C 4-8 Alkyl (eg C4 alkyl, such as n-butyl); and / or (eg and)

[0330] R 2 and R 3 All represent H.

[0331] In a more specific embodiment, a compound of formula IB is provided, wherein:

[0332] n represents 1 and the F atom is located at the 4-position of the phenyl group;

[0333] R 1 Represents C 4-8 Alkyl (eg, C4 alkyl, such as n-butyl); and

[0334] R 2 and R 3 All represent H.

[0335] In specific embodiments that may be mentioned, the essential -OH group in the compounds of the formula I is in the (R) configuration.

[0336] In yet more specific embodiments, the compound of formula I (or the compound of formula IA or the compound of formula IB) is a compound of formula IC

[0337]

[0338] where Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , R 1 , R 2 and R 3 As described herein (ie as described in the first aspect of the invention including all embodiments and specific features and combinations thereof).

[0339] For example, a compound of formula IC is provided, wherein:

[0340] Y 1 , Y 4 and Y 5 Each represents H;

[0341] Y 2 and Y 3 One of them represents F and the other represents H;

[0342] R 1 Represents C 4-5 Alkyl; and / or

[0343] R 2 and R 3 All represent H.

[0344] As described herein, specific compounds of the first aspect of the invention that may be mentioned include compounds of the examples provided herein and pharmaceutically acceptable salts thereof. Thus, compounds of formula IB or IC that may be mentioned include:

[0345] (R)-2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0346] (R)-2-(Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0347] (R)-2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0348] (R)-1-(4-Fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol

[0349] (R)-1-(4-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0350] (R)-1-(3-Fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol

[0351] (R)-1-(3-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0352] and pharmaceutically acceptable salts thereof.

[0353] Specific compounds of formula I (eg, compounds of formula IB or IC) include:

[0354] (R)-2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0355] (R)-2-(Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0356] (R)-2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0357] and pharmaceutically acceptable salts thereof.

[0358] Certain specific compounds of formula I include:

[0359] (R)-1-(4-Fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol

[0360] (R)-1-(4-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0361] (R)-1-(3-Fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol

[0362] (R)-1-(3-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0363] and pharmaceutically acceptable salts thereof.

[0364] Additional compounds of the formula I (eg compounds of the formula IB or IC) that may be mentioned include:

[0365] (R)-1-(3-Fluorophenyl)-2-((2-methylpentan-2-yl)amino)ethan-1-ol

[0366] (R)-2-(tert-Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0367] (R)-2-(Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0368] (R)-2-(tert-Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0369] (R)-2-(Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0370] (R)-2-(2-(tert-Butylamino)-1-hydroxyethyl)-5-fluorophenol

[0371] (R)-2-(2-(Butylamino)-1-hydroxyethyl)-5-fluorophenol

[0372] (R)-1-(3-Fluorophenyl)-2-((1-methylcyclobutyl)amino)ethan-1-ol

[0373] (R)-1-(3-Fluorophenyl)-2-((1-methylcyclopropyl)amino)ethan-1-ol

[0374] (R)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0375] (R)-5-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0376] (R)-3-(2-(tert-Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0377] (R)-3-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0378] (R)-1-(3-amino-2-fluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0379] (R)-1-(3-Amino-2-fluorophenyl)-2-(butylamino)ethan-1-ol

[0380] (R)-1-(3-Fluorophenyl)-2-(neopentylamino)ethan-1-ol

[0381] (R)-1-(3-Fluorophenyl)-2-((1-(trifluoromethyl)cyclopropyl)amino)ethan-1-ol

[0382] (R)-1-(3-amino-2,4-difluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0383] (R)-2-(tert-Butylamino)-1-(3-fluoro-2-methylphenyl)ethan-1-ol

[0384] and pharmaceutically acceptable salts thereof.

[0385] In certain embodiments that may be mentioned, the compound of the present invention is not a compound selected from the list consisting of:

[0386] (R)-2-(tert-butylamino)-1-(3-fluorophenyl)ethan-1-ol; and

[0387] (R)-1-(4-Fluorophenyl)-2-((-pentan-2-yl)amino)ethan-1-ol.

[0388] In further embodiments that may be mentioned, the compound of the invention is not a compound selected from the list consisting of:

[0389] (R)-2-(tert-butylamino)-1-(3-fluorophenyl)ethan-1-ol; and

[0390] (R)-1-(4-Fluorophenyl)-2-((-pentan-2-yl)amino)ethan-1-ol

[0391] and pharmaceutically acceptable salts thereof.

[0392] The skilled artisan will understand that reference to a particular stereoisomer of a compound of Formula I (e.g., in the case of a compound of Formula I, wherein the carbon substituted with an essential -OH group is in the (R) configuration as shown in compounds of Formula IB and IC) will refer to the presence of that particular stereoisomer in the substantial absence of the corresponding opposite stereoisomer (e.g., in the case of a compound of Formula I, wherein the carbon substituted with an essential -OH group is in the (S) configuration).

[0393] For example, reference to a compound of Formula IC being present in the substantial absence of the corresponding opposite stereoisomer (ie, in the (S) configuration) will refer to the substantial absence of the corresponding compound, as depicted below.

[0394]

[0395] As used herein, reference to the substantial absence of other stereoisomers (e.g., the corresponding opposite stereoisomer) will refer to the purity of the desired stereoisomer (e.g., in the case of a compound of Formula I, wherein the carbon substituted by the essential -OH group is in the (R) configuration) relative to the other stereoisomers (e.g., in the case of a compound of Formula I, wherein the carbon substituted by the essential -OH group is in the (S) configuration) being at least 80% (e.g., at least 90%, such as at least 95%). Alternatively, in this case, it can be indicated that the compound is present in the substantial absence of the compound of the other configuration (i.e., the (S) configuration), which can indicate that the compound of the relevant configuration is present in an enantiomeric excess (ee) or diastereomeric excess (de), as the case may be, of at least 90% (e.g., at least 95%, at least 98%, or in particular at least 99%, such as at least 99.9%).

[0396] For the avoidance of doubt, a compound referred to as having a particular stereochemistry at a defined position (e.g., in the case of a compound of Formula I, the carbon substituted with an essential -OH group is in the (R) configuration) may also have stereochemistry at one or more other positions, and may therefore exist as a mixture of enantiomers or diastereomers with respect to stereochemistry at these positions.

[0397] Medical Uses

[0398] As indicated herein, the compounds of the invention, as well as compositions and kits comprising the compounds of the invention, are useful as medicaments.

[0399] Therefore, according to a second aspect of the present invention, there is provided a compound as defined above in the first aspect of the present invention (i.e. a compound as defined in the first aspect of the present invention, including all embodiments and specific features thereof) for use as a medicament (or for use in a medicament).

[0400] For the avoidance of doubt, references to compounds defined in accordance with the first aspect of the invention will include references to compounds of formula I (including all embodiments thereof) and pharmaceutically acceptable salts thereof.

[0401] As indicated herein, the compounds of the invention may be particularly useful for treating hyperglycemia or a disease characterized by hyperglycemia.

[0402] Thus, in a third aspect of the present invention there is provided a compound according to the first aspect of the present invention as defined above for use in the treatment of hyperglycemia or a disease characterised by hyperglycemia.

[0403] In an alternative third aspect of the present invention, there is provided a use of a compound of formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating hyperglycemia or a disease characterized by hyperglycemia.

[0404] In another alternative third aspect of the present invention, there is provided a method for treating hyperglycemia or a disease characterized by hyperglycemia, the method comprising administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to a patient in need thereof.

[0405] For the avoidance of doubt, those skilled in the art will appreciate that, as used herein, the term "hyperglycemia" refers to a condition in which an excess of glucose circulates in the plasma of a subject experiencing the condition. Specifically, hyperglycemia may refer to a subject (e.g., a human subject) whose blood glucose level is above about 10.0 mmol / L (e.g., above about 11.1 mmol / L, e.g., above about 15 mmol / L), but hyperglycemia may also refer to a subject (e.g., a human subject) whose blood glucose level is above about 7 mmol / L for a prolonged period of time (e.g., greater than 24 hours, e.g., greater than 48 hours).

[0406] Technicians will understand that the reference to the treatment of a particular condition (or similarly, treating the condition) adopts its normal meaning in the medical field. Specifically, the term may refer to the reduction of the severity of one or more clinical symptoms associated with the condition. For example, in the case of type 2 diabetes, the term may refer to the reduction of blood sugar levels. In a specific embodiment, in the case of treating hyperglycemia or a condition characterized by hyperglycemia, the term may refer to the reduction of blood sugar levels (for example, reaching or being lower than about 10.0mmol / mL (for example, reaching a level in the range of about 4.0mmol / L to about 10.0mmol / L), such as reaching or being lower than about 7.5mmol / mL (for example, reaching a level in the range of about 4.0mmol / L to about 7.5mmol / L) or reaching or being lower than 6mmol / mL (for example, reaching a level in the range of about 4.0mmol / L to about 6.0mmol / L)).

[0407] As used herein, reference to a patient will refer to a living being treated, including a mammalian (eg, human) patient. Thus, in a particular embodiment of the first aspect of the invention, the treatment is performed in a mammal (eg, a human).

[0408] As used herein, the term therapeutically effective amount shall refer to the amount of a compound that confers a therapeutic effect on a treated patient. The effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives an indication and / or feels the effect).

[0409] Although the compounds of the first aspect of the invention may themselves have pharmacological activity, certain pharmaceutically acceptable (e.g., "protected") derivatives of the compounds of the invention may exist or be prepared to not have such activity, but may be administered parenterally or orally, and then metabolized in vivo to form the compounds of the invention. Such compounds (which may have some pharmacological activity, provided that such activity is significantly lower than the activity of the active compound to which it is metabolized) may therefore be described as "prodrugs" of the compounds of the invention.

[0410] As used herein, reference to a prodrug will include compounds that form a compound of the invention in an experimentally detectable amount within a predetermined time following enteral or parenteral administration (e.g., oral or parenteral administration). All prodrugs of the compounds of the first aspect of the invention are included within the scope of the invention.

[0411] For the avoidance of doubt, the compounds of the first aspect of the invention are useful because the compounds are pharmacologically active and / or are metabolized in vivo to form pharmacologically active compounds after oral or parenteral administration. Specifically, as described herein, the compounds of the first aspect of the invention can be used to treat hyperglycemia or diseases characterized by hyperglycemia (such as type 2 diabetes), and those skilled in the art will readily understand the term hyperglycemia (as described herein).

[0412] In specific embodiments, the treatment is of a condition (also referred to as a disorder or disease) characterized by hyperglycemia.

[0413] In specific embodiments, the compounds of the invention (ie, compounds of Formula I, including all embodiments thereof) are used to treat type 2 diabetes (or can be used to manufacture a medicament for such treatment, or can be used in a method for such treatment, as described herein).

[0414] In a particular embodiment of the first aspect of the invention, the disease is type 2 diabetes, such as a subtype of type 2 diabetes selected from the list consisting of maturity-onset diabetes (MODY), ketosis-onset diabetes in adults, latent autoimmune diabetes in adults (LADA) and gestational diabetes.

[0415] In another specific embodiment, type 2 diabetes is treated in a non-obese patient.

[0416] For the avoidance of doubt, the skilled artisan will appreciate that a patient with a body mass index (BMI) greater than 30 is considered obese.

[0417] In a specific embodiment, the treatment may be directed to hyperglycemia in patients at risk for type 2 diabetes, which condition may be defined as prediabetes. Thus, the compounds of the invention may be used to prevent type 2 diabetes (e.g., in patients with prediabetes).

[0418] As used herein, the term prevention (prevention) (and similarly, prevention (preventing)) includes reference to the prevention (prophylaxis) of a disease or condition (and vice versa). Therefore, reference to prevention (prevention) may also refer to prophylaxis, and vice versa. Specifically, the term may refer to achieving a reduction in the likelihood that a patient (or healthy subject) will become ill (e.g., a reduction of at least 10%, such as a reduction of at least 20%, 30% or 40%, such as a reduction of at least 50%).

[0419] In more specific embodiments, type 2 diabetes is characterized in that patients exhibit severe insulin resistance (SIR).

[0420] In further embodiments, the treatment may be for hyperglycemia in patients with type 1 diabetes. Thus, the compounds of the present invention may be used to treat hyperglycemia in type 1 diabetes.

[0421] The skilled artisan will appreciate that the compounds of the invention may be used to treat hyperglycemia in patients with impaired insulin secretion, such as patients with cystic fibrosis. Thus, in further embodiments, the disease characterized by hyperglycemia is cystic fibrosis-associated diabetes.

[0422] In a specific embodiment that may be mentioned, the disease characterized by hyperglycemia is (or is characterized by) severe insulin resistance (SIR), which can be understood by those skilled in the art to refer to such a disease: wherein the subject usually has normal insulin secretion, or in some cases has increased insulin secretion but significantly reduced insulin sensitivity. In specific cases, such patients can be non-obese (e.g., have a healthy weight). Therefore, in a specific embodiment, such treatment is performed in patients who are not defined as obese (e.g., in patients who are defined as having a healthy weight).

[0423] For example, SIR can be identified in patients based on their fasting insulin >150 pmol / L and / or peak insulin >1,500 pmol / L on a glucose tolerance test, particularly in patients with a BMI <30 kg / m 2 SIRs are identified in patients who otherwise have normal glucose tolerance.

[0424] More specifically, SIR can be characterized by the patient's failure to respond significantly to the presence of insulin, possibly due to a defect in insulin receptor function (eg, a genetic defect).

[0425] Specific diseases that may be characterized by SIR include: Rabson-Mendenhall syndrome, Donohue syndrome (dwarfism), insulin resistance syndrome types A and B, HAIR-AN (hyperandrogenism, insulin resistance, and acanthosis nigricans) syndrome, pseudoacromegaly, and lipodystrophy.

[0426] More specific disorders that may be characterized by SIR include Donohue syndrome and type A insulin resistance syndrome, but more specifically, Rabson-Mendenhall syndrome.

[0427] The skilled person will appreciate that, for the same disease, treatment with the compound of the first aspect of the present invention may further include additional (i.e., additional / other) one or more treatments, i.e., in combination with the additional one or more treatments. Specifically, treatment using the compound of the present invention may be combined with other means for treating type 2 diabetes, such as treatment with one or more other therapeutic agents known to those skilled in the art that can be used for treating type 2 diabetes, such as including a therapy requiring the patient to change diet and / or perform an exercise regimen, and / or a surgical procedure (e.g., gastric band surgery) intended to promote weight loss.

[0428] Specifically, treatment with the compounds of the invention can be performed in combination with (e.g., in a patient also being treated with) one or more (e.g., one) of the following additional compounds (i.e., therapeutic agents):

[0429] (i) a compound capable of lowering blood sugar levels; and / or

[0430] (ii) compounds that act as insulin sensitizers; and / or

[0431] (iii) compounds that enhance insulin release,

[0432] All of these compounds are described below.

[0433] In an alternative embodiment, the compounds of the first aspect of the invention (ie the compounds of the invention) may be used to treat non-alcoholic fatty liver disease (NAFLD).

[0434] Nonalcoholic fatty liver disease (NAFLD) is defined by excessive accumulation of fat in the form of triglycerides (steatosis) in the liver, which is defined histologically as accumulation in greater than 5% of hepatocytes. Nonalcoholic fatty liver disease is the most common liver disease in developed countries (e.g., affecting about 30% of American adults), and most patients are asymptomatic. If left untreated, the condition may gradually worsen and eventually lead to cirrhosis. NAFLD is particularly prevalent in obese patients, with approximately 80% of obese patients suffering from the disease.

[0435] A subgroup of patients with NAFLD (e.g., between 2% and 5% of U.S. adults) exhibit hepatocellular damage and inflammation in addition to excess fat accumulation. This condition, known as nonalcoholic steatohepatitis (NASH), is virtually histologically indistinguishable from alcoholic steatohepatitis. Although the simple steatosis observed in NAFLD is not directly associated with increased short-term morbidity or mortality, the progression of this condition to NASH greatly increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma. In fact, NASH is now considered one of the leading causes of cirrhosis (including cryptogenic cirrhosis) in developed countries.

[0436] The exact cause of NASH has not been elucidated and is almost certainly different in every patient. NASH is closely associated with insulin resistance, obesity, and metabolic syndrome (which includes conditions associated with type 2 diabetes, insulin resistance, central (truncal) obesity, hyperlipidemia, low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, and hypertension). However, not all patients with these conditions have NASH, and not all patients with NASH have one of these conditions. However, given that NASH is a potentially fatal condition that can lead to cirrhosis, liver failure, and hepatocellular carcinoma, there is a clear need for effective treatments.

[0437] In specific embodiments, the compounds of the invention (i.e., compounds of Formula I, including all embodiments thereof) are used to treat non-alcoholic fatty liver disease (or can be used to manufacture a medicament for such treatment, or can be used in a method for such treatment, as described herein).

[0438] The process by which triglyceride fat accumulates in liver cells is called steatosis (i.e., hepatic steatosis). The skilled person will appreciate that the term "steatosis" encompasses abnormal retention of fat (i.e., lipid) within cells. Therefore, in a specific embodiment of the first aspect of the invention, treatment or prevention is directed to fatty liver disease characterized by steatosis.

[0439] During steatosis, excess lipids accumulate in vesicles that replace the cell's cytoplasm. Over time, the vesicles can grow large enough to deform the cell nucleus, a condition known as macrovesicular steatosis. Alternatively, the condition may be referred to as microcystic steatosis. In mild cases, steatosis is largely harmless; however, the accumulation of large amounts of fat in the liver can cause significant health problems. Risk factors associated with steatosis include diabetes, protein malnutrition, hypertension, obesity, hypoxia, sleep apnea, and the presence of toxins within cells.

[0440] As described herein, fatty liver disease is most commonly associated with alcohol or metabolic syndrome (e.g., diabetes, hypertension, obesity, or dyslipidemia). Thus, fatty liver disease can be diagnosed as alcohol-related fatty liver disease or non-alcoholic fatty liver disease (NAFLD), depending on the underlying cause.

[0441] Specific diseases or conditions associated with nonalcoholic fatty liver disease include metabolic conditions such as diabetes, hypertension, obesity, dyslipidemia, abetalipoproteinemia, glycogen storage disease, Weber–Christian disease, acute fatty liver of pregnancy, and lipodystrophy. Other nonalcoholic factors associated with fatty liver disease include malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejunoileal bypass, gastric bypass, polycystic ovary syndrome, and intestinal diverticular disease.

[0442] The compounds of the present invention have been found to be particularly useful in treating or preventing NAFLD, which may be referred to as non-alcohol related fatty liver disease. "Non-alcohol related" fatty liver disease may be diagnosed where the patient's alcohol consumption is not considered to be the primary cause. Typical thresholds for diagnosing fatty liver disease as "non-alcohol related" are: daily intake of less than 20 g for female subjects and less than 30 g for male subjects.

[0443] If left untreated, subjects with fatty liver disease may begin to experience liver inflammation (hepatitis). It is speculated that one of the possible causes of this inflammation may be peroxidative damage to the liver cell membranes by lipids. Inflammation of fatty liver may lead to many serious conditions, and therefore, it is desirable to treat or prevent fatty liver before inflammation occurs. Therefore, in a specific embodiment of the first aspect of the invention, treatment or prevention is directed to NAFLD associated with inflammation.

[0444] Non-alcoholic fatty liver disease (NASH) is the most serious form of NAFLD, and is a condition in which fat accumulates excessively (fatty degeneration) and is accompanied by liver inflammation. If it reaches the late stage, NASH can lead to the development of scar tissue in the liver (fibrosis), and eventually lead to cirrhosis. As described above, it has been found that the compounds of the present invention can be used to treat or prevent NAFLD, particularly when accompanied by liver inflammation. Therefore, the compounds of the present invention can also be used to treat or prevent NASH. Therefore, in another embodiment of the first aspect of the present invention, treatment or prevention is for non-alcoholic fatty liver disease (NASH).

[0445] The skilled person will understand that for the same condition, treatment with the compound of the first aspect of the present invention may further include one or more additional (i.e., additional / other) treatments, i.e., in combination with the additional one or more treatments. Specifically, treatment using the compound of the present invention may be combined with other means described herein for treating fatty liver disease, such as treatment with one or more other therapeutic agents known to those skilled in the art that can be used to treat fatty liver disease; for example, including therapy requiring the patient to change diet and / or perform an exercise regimen, and / or a surgical procedure intended to promote weight loss (e.g., gastric band surgery).

[0446] In particular, treatment with the compounds of the invention can be carried out in combination with one or more (e.g., one) additional compounds (i.e., therapeutic agents) that are capable of reducing fat (e.g., triglyceride) levels in the liver (e.g., in a patient also being treated with the additional compound).

[0447] Reference to treatment of fatty liver disease may refer to achieving a therapeutically significant reduction in fat (eg, triglyceride levels) in hepatocytes (eg, at least a 5% reduction in weight, such as at least a 10% reduction, or at least a 20% or even a 25% reduction).

[0448] Pharmaceutical composition

[0449] As described herein, the compounds of the first aspect of the present invention (ie, the compounds of the present invention) can be used as medicaments. Such compounds can be administered alone or in the form of known pharmaceutical compositions / formulations.

[0450] In the fourth aspect of the present invention, a pharmaceutical composition is provided, comprising the compound according to the second or third aspect of the present invention, and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers.

[0451] The skilled person will appreciate that references herein to compounds of the first aspect of the invention for particular uses (and similarly, references to uses and methods of use involving compounds of the invention) may also apply to pharmaceutical compositions comprising a compound of the invention as described herein.

[0452] In a fifth aspect of the present invention, a pharmaceutical composition for treating hyperglycemia or a disease characterized by hyperglycemia (as defined herein, such as type 2 diabetes) is provided, the pharmaceutical composition comprising a compound according to the first aspect of the present invention, and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers.

[0453] In an alternative fifth aspect of the present invention there is provided a pharmaceutical composition for use in the treatment or prevention of non-alcoholic fatty liver disease as defined herein.

[0454] The skilled person will appreciate that the compounds of the first aspect of the invention may act systemically and / or locally (ie at a specific site).

[0455] The skilled person will appreciate that the compounds and compositions according to the first to fifth aspects of the present invention will generally be administered orally, intravenously, subcutaneously, orally, rectally, dermally, nasally, tracheally, bronchially, sublingually, intranasally, topically, any other parenteral route or by inhalation in a pharmaceutically acceptable dosage form. The pharmaceutical compositions described herein will include compositions for oral administration in the form of tablets, capsules or elixirs, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, etc. Alternatively, in particular in the case where such compounds of the present invention act locally, pharmaceutical compositions may be formulated for topical administration.

[0456] Therefore, in the specific embodiments of the fourth and fifth aspects of the present invention, the pharmaceutical formulation is provided in a pharmaceutically acceptable dosage form, including tablets or capsules, oral or injectable liquid forms, suppositories, creams, gels, foams, inhalants (e.g., intranasal applications) or forms suitable for topical administration. For the avoidance of doubt, in such embodiments, the compounds of the present invention may be in solid form (e.g., solid dispersions), liquid form (e.g., solutions) or in other forms (e.g., in the form of micelles).

[0457] For example, in the preparation of a pharmaceutical formulation for oral administration, the compound can be mixed with a solid powdered ingredient (such as lactose, sucrose, sorbitol, mannitol, starch, pullulan, cellulose derivatives, gelatin or other suitable ingredients), and with a disintegrant and a lubricant (such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol wax). The mixture can then be processed into granules or compressed into tablets.

[0458] Soft gelatin capsules can be prepared with capsules containing one or more active compounds (e.g., compounds of the first aspect of the invention and therefore the second and third aspects, and optionally additional therapeutic agents) and, for example, vegetable oils, fats or other carriers suitable for soft gelatin capsules. Similarly, hard gelatin capsules can contain this or these compounds in combination with solid powdered ingredients (e.g., lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, pullulan, cellulose derivatives or gelatin).

[0459] Dosage units for rectal administration can be prepared in the form of: (i) suppositories containing one or more compounds mixed with a neutral fat base; (ii) gelatin rectal capsules containing the active material mixed with vegetable oils, paraffin oil or other carriers suitable for gelatin rectal capsules; (iii) ready-to-use microenemas; or (iv) dry microenema formulations to be reconstituted in a suitable solvent immediately before administration.

[0460] The liquid preparation for oral administration can be prepared into the form of syrup or suspension, for example solution or suspension, and the syrup or suspension contain the remainder of one or more compounds and formulation, and the formulation is composed of the mixture of sugar or sugar alcohol and ethanol, water, glycerine, propylene glycol and polyethylene glycol. If necessary, this liquid preparation can contain coloring agent, flavoring agent, saccharin and carboxymethyl cellulose or other thickening agents. The liquid preparation for oral administration can also be prepared into the form of dry powder, redissolve with suitable solvent before use.

[0461] Solutions for parenteral administration can be prepared as solutions of one or more compounds in a pharmaceutically acceptable solvent. These solutions can also contain stabilizing ingredients and / or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration can also be prepared as dry preparations and reconstituted with a suitable solvent immediately before use.

[0462] It will be appreciated by the skilled person that the compounds of the present invention and their pharmaceutically acceptable salts can be administered in different doses (e.g., in the form of formulations described above), and appropriate dosages are easily determined by those skilled in the art. Oral doses, pulmonary doses, and local doses (as well as subcutaneous doses, but these doses may be relatively low) can be in the range of about 0.01 μg / kg body weight / day (μg / kg / day) to about 200 μg / kg / day (preferably about 0.01 μg / kg / day to about 10 μg / kg / day, and more preferably about 0.1 μg / kg / day to about 5.0 μg / kg / day). For example, when administered orally, treatment with such compounds can include administering formulations containing one or more active ingredients generally between about 0.01 μg and about 2000 mg, such as between about 0.1 μg and about 500 mg, or between 1 μg and about 100 mg (e.g., about 20 μg to about 80 mg). When administered intravenously, the most preferred dosage range will be about 0.001 μg / kg / hour to about 10 μg / kg / hour during a constant rate infusion. Advantageously, treatment may include administration of such compounds and compositions in a single daily dose, or the total daily dose may be administered in divided doses twice, three or four times a day (e.g., with reference to the doses described herein, twice a day, such as a dose of 10 mg, 20 mg, 30 mg or 40 mg, twice a day, or a dose of 10 μg, 20 μg, 30 μg or 40 μg, twice a day).

[0463] In any case, the technician (e.g., physician) will be able to determine the actual dosage that is most suitable for an individual patient, which may vary with the route of administration, the type and severity of the disorder to be treated, and the species, age, weight, sex, renal function, liver function, and response of the specific patient to be treated. The dosages mentioned above are exemplary in general; of course, in individual cases, higher or lower dosage ranges may be required, and such dosage ranges are within the scope of the present invention.

[0464] As described herein above, it will be appreciated by the skilled person that, for the same condition, treatment with the compound of the first aspect of the present invention may further include additional (i.e., additional / other) one or more treatments, i.e., in combination with the additional one or more treatments. Specifically, treatment using the compound of the present invention may be combined with other means for treating hyperglycemia or a disease characterized by hyperglycemia (as defined herein, such as type 2 diabetes), such as with one or more other therapeutic agents that can be used to treat hyperglycemia or a disease characterized by hyperglycemia (as defined herein, such as type 2 diabetes).

[0465] In particular embodiments of the fourth and fifth aspects of the invention, the pharmaceutical composition may further comprise one or more additional (ie, other) therapeutic agents.

[0466] In more specific embodiments, the one or more additional therapeutic agents are agents known to those skilled in the art for the treatment of type 2 diabetes, such as metformin, sulfonylureas (e.g., sulfabutamide, acetohexamide, chlorpropamide, tolbutamide, glipizide (glyburide), gliclazide, glibenclamide, glibenclamide (glyburide), gliprexa, gliclazide, glimepiride, glimepiride (Amaryl), glimepiride, JB253 or JB558), thiazolidinediones (e.g., pioglitazone, rosiglitazone (Avandia), gliclazide, gliclazide, gliclazide, gliclazide, glimepiride (Amaryl), glimepiride, JB253 or JB558), andia), lobeglitazone (Duvie) and troglitazone (Rezulin)), dipeptidyl peptidase 4 inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, rilagliptin, alogliptin, trelagliptin, gemagliptin, dutogliptin and omagliptin), SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, topagliflozin, sergliflozin etabonate, repagliflozin etabonate and eptigliptin) and glucagon-like peptide 1 (GLP-1) analogs.

[0467] The skilled artisan will appreciate that combinations of therapeutic agents may also be described as a combination product and / or provided as a kit-of-parts.

[0468] In a sixth aspect of the present invention, there is provided a combination product comprising:

[0469] (A) the compound according to the first aspect of the present invention; and

[0470] (B) one or more additional therapeutic agents,

[0471] Each of components (A) and (B) is optionally formulated in the form of an admixture together with one or more pharmaceutically acceptable adjuvants, diluents or carriers.

[0472] In a seventh aspect of the present invention, a kit is provided, comprising:

[0473] (a) a compound according to the first aspect of the invention (or a pharmaceutical composition comprising the compound) or a pharmaceutical composition according to the fourth or fifth aspect of the invention; and

[0474] (b) one or more other therapeutic agents, optionally in admixture with one or more pharmaceutically acceptable adjuvants, diluents or carriers,

[0475] The components (a) and (b) are each provided in a form suitable for administration in combination with one another.

[0476] In specific embodiments (e.g., in specific embodiments of the sixth and seventh aspects of the invention), the additional therapeutic agent is a therapeutic agent known to those skilled in the art to be useful for treating hyperglycemia or a disease characterized by hyperglycemia (e.g., type 2 diabetes) (e.g., a therapeutic agent described herein).

[0477] For example, in specific embodiments of the fourth to seventh aspects of the invention, the additional therapeutic agent is the following agent:

[0478] (i) an agent capable of lowering blood glucose levels; and / or

[0479] (ii) an agent that acts as an insulin sensitizer; and / or

[0480] (iii) agents capable of enhancing insulin release,

[0481] Such agents will be readily identifiable by those skilled in the art, and specifically include such therapeutic agents that are commercially available (eg, the subject of marketing authorization in one or more regions, such as European or American marketing authorizations).

[0482] The skilled person will understand that reference to a therapeutic agent capable of lowering blood glucose levels may refer to a compound capable of lowering blood levels by at least 10% (e.g. at least 20%, at least 30% or at least 40%, for example at least 50%, at least 60%, at least 70% or at least 80%, for example at least 90%) when compared to blood glucose levels prior to treatment with the relevant compound.

[0483] In alternative embodiments of the sixth and seventh aspects of the invention, the additional therapeutic agent is an agent for treating or preventing non-alcoholic fatty liver disease (such as NASH), which will be readily identified by a person skilled in the art and specifically includes such therapeutic agents that are commercially available (e.g., those that have obtained market authorization in one or more regions, such as agents authorized for the European or US markets).

[0484] Preparation of compounds / compositions

[0485] The pharmaceutical compositions / formulations, combination products and kits described herein may be prepared in accordance with standard and / or accepted pharmaceutical practice.

[0486] Thus, in a further aspect of the invention there is provided a process for the preparation of a pharmaceutical composition / formulation as defined above, said process comprising bringing into association a compound of the invention as defined above with one or more pharmaceutically acceptable adjuvants, diluents or carriers.

[0487] In a further aspect of the invention, there is provided a process for preparing a combination product or kit of parts as defined above, the process comprising associating a compound of the invention as defined above, or a pharmaceutically acceptable salt thereof, with other therapeutic agents useful for treating hyperglycemia or a disease characterized by hyperglycemia (e.g., type 2 diabetes) and at least one pharmaceutically acceptable adjuvant, diluent or carrier.

[0488] As used herein, reference to associating shall mean rendering two components suitable for administration in conjunction with one another.

[0489] Thus, with respect to a process for preparing a kit of parts as defined above by "associating" two components with each other, we include that the two components of the kit of parts may:

[0490] (i) provided as separate formulations (i.e. independently of each other) which are subsequently combined together for use in conjunction with each other in a combination therapy; or

[0491] (ii) the individual components are packaged and presented together as a "combination pack" for use in conjunction with each other in a combination therapy.

[0492] The compounds according to the first aspect of the invention (ie the compounds of the invention) can be prepared according to techniques well known to those skilled in the art, such as those described in the examples provided below.

[0493] For example, a process for preparing a compound of formula I or a pharmaceutically acceptable salt thereof according to the first aspect of the present invention is provided (which can be used to prepare, for example, a compound according to the second aspect of the present invention), the process comprising:

[0494] (i) making the compound of formula II

[0495]

[0496] Where X 1 , X 2 , X 3 , X 4 , R 2 and R 3 As defined above, with a compound of formula III

[0497] H2N-R 1 (III)

[0498] Where R 1 as defined above, optionally reacting in the presence of a suitable solvent known to those skilled in the art;

[0499] (iia) the compound of formula IV

[0500]

[0501] Where m, n, X, R 1 , R 2 and R 3 As defined above, and Y 1 Indicates H or PG 1 , where PG 1 is a suitable protecting group known to those skilled in the art (e.g., -C(O)OtBu or -SO2CH3), reacted with a suitable reducing agent known to those skilled in the art (e.g., NaBH4 or LiAlH4, or a suitable chiral reducing agent), or by hydrogenation in the presence of a suitable catalyst (e.g., a chiral catalyst or additive);

[0502] (iib) For compounds of formula IB (and similarly, compounds of formula IC), a compound of formula IV as defined above, but wherein Y 1 Indicates PG 1 , where PG 1 is a suitable protecting group known to those skilled in the art (e.g., -C(O)OtBu), in the presence of a suitable catalyst (e.g., a complex between (1S,2S)-(+)-N-(4-tosyl)-1,2-diphenylethylenediamine and [Ru(isopropyltoluene)Cl2]2), in the presence of hydrogen or a suitable hydrogen donor (e.g., formic acid), and optionally in the presence of a base (e.g., Et3N) and in the presence of a suitable solvent (e.g., CH2Cl2);

[0503] (iii) for compounds wherein at least one X is present and said X represents -OH, deprotecting the compound of formula V under conditions known to those skilled in the art

[0504]

[0505] Where m, n, R 1 , R 2 and R 3 As defined above, Y 2 Indicates H or PG 2 , where PG 2 represents a suitable protecting group known to those skilled in the art, and PG 3 represents a suitable protecting group known to those skilled in the art (e.g., benzyl or alkyl, such as methyl) (e.g., in the case of benzyl, deprotection is carried out in the presence of hydrogen and a suitable catalyst or a suitable acid; in the case of alkyl (e.g., methyl), deprotection is carried out in the presence of BBr3, HBr or alkyl sulfide);

[0506] (iv) for compounds wherein at least one X is present and said X represents NH2 or NHC(O)CH3, deprotecting the compound of formula VI under conditions known to those skilled in the art

[0507]

[0508] Where m, n, X, R 1 , R 2 and R 3 As defined above, Y 3 Indicates H or PG 5 , where PG 5 represents a suitable protecting group known to those skilled in the art, Y 4 Indicates H, C(O)CH3 or PG 6 , where PG 6 represents a suitable protecting group known to those skilled in the art, and PG 4 represents a suitable protecting group known to those skilled in the art (e.g., carbamate protecting groups such as tert-butyloxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc) and carboxybenzyl (Cbz) and amide protecting groups such as acetyl and benzoyl) (e.g., in the case of Boc, deprotection is carried out in the presence of a suitable acid such as trifluoroacetic acid or HCl). PG 4 PG 5 (if present) and PG 6 (if present) may each represent the same protecting group and thus be deprotected under one set of conditions;

[0509] (v) for compounds wherein at least one X is present and said X represents NH2, reducing the compound of formula VII under conditions known to those skilled in the art

[0510]

[0511] Where m, n, X, R 1 , R 2 and R 3 As defined above (e.g., by hydrogenation, such as using hydrogen and a suitable catalyst known to those skilled in the art (e.g., Pd-C, PtO2, Raney nickel), iron or zinc in an acidic medium (e.g., AcOH), borohydride and a suitable catalyst (e.g., NaBH4 and Raney nickel) or reagent (e.g., SnCl2, TiCl3, SmI2), etc.). Those skilled in the art will appreciate that during the reaction, it may be necessary to remove certain functional groups (e.g., essential -OH groups and / or -NHR groups) 1 The protection (and deprotection) can be performed one or more times using techniques known to those skilled in the art.

[0512] Compounds of formula II, III, IV, V, VI and VII are commercially available, known in the literature, or can be obtained from available starting materials (e.g., appropriately substituted benzaldehyde, styrene or benzoyl bromide (or benzoyl chloride, etc.) by processes similar to those described herein or by conventional synthetic procedures according to standard techniques using appropriate reagents and reaction conditions. In this regard, the skilled person can refer in particular to Comprehensive Organic Synthesis, BMTrost and I. Fleming, Pergamon Press, 1991. Additional references that may be employed include Science of Synthesis, Vol. 9-17 (Hetarenes and Related Ring Systems), Georg Thieme Verlag, 2006.

[0513] Substituents X, R as defined above 1 , R 2 and R 3Can be modified once or many times after or during the above-mentioned process for preparing compound of formula I by methods well known to those skilled in the art.The example of such method comprises substitution, reduction, oxidation, dehydrogenation, alkylation, dealkylation, acylation, hydrolysis, esterification, etherification, halogenation and nitration.At any time during the reaction sequence, the precursor group can be changed to different such groups, or changed to the group defined in formula I.Technicians can also refer to ARKatritzky, O.Meth-Cohn and CWRees " Comprehensive Organic Functional Group Transformations ", Pergamon Press, 1995 and / or RCLarock " Comprehensive Organic Transformations ", Wiley-VCH Press, 1999.

[0514] Such compounds can be isolated from their reaction mixtures and, if desired, purified using conventional techniques known to those skilled in the art. Thus, the process for preparing the compounds of the invention as described herein may comprise isolating and optionally purifying the compounds of the invention as a final step (e.g., isolating and optionally purifying a compound of Formula I or a compound of IA).

[0515] The skilled artisan will appreciate that compounds of formula I (eg, compounds of formula IB and IC) having a specific stereochemistry can be provided by reacting appropriate starting materials having the desired stereochemistry in the processes described herein.

[0516] For example, compounds of formula IB and IC may be provided by reacting compounds having the desired stereochemistry as described in step (i) or step (iii) of the processes described herein above.

[0517] Furthermore, the skilled artisan will appreciate that suitable starting materials having the desired stereochemistry (such as suitable compounds of formula II and formula V required to prepare compounds of formula IB and IC, wherein the carbon substituted by the necessary oxygen is in the (R) configuration) may be prepared by processes analogous to those described in step (iib) above.

[0518] Those skilled in the art will appreciate that in the processes described above and below, the functional groups of the intermediate compounds may need to be protected by protecting groups. The functional groups may be protected and deprotected before or after the reactions in the above schemes.

[0519] Blocking groups can be applied and removed according to the technology well known to those skilled in the art and as described below.For example, the deprotection technique of standard can be used, protected compound / intermediate described herein is converted into unprotected compound with chemical method.The chemical type involved will indicate the demand and type of blocking group, and the order for completing synthesis.The purposes of blocking group are fully described in TWGreene and PGM Wutz's " Protective Groups in Organic Synthesis ", the 3rd edition, Wiley-Interscience (Wiley-Interscience) (1999).

[0520] The compounds described herein (in particular, the compounds defined in the first aspect of the invention and therefore the second and third aspects) may have the following advantages: the compounds may be more effective, less toxic, longer acting, more potent, produce fewer side effects, be more easily absorbed and / or have better pharmacokinetic characteristics (e.g., higher oral bioavailability and / or lower clearance) and / or have other useful pharmacological, physical or chemical properties than compounds known in the prior art, whether or not used or otherwise for the above indications. In particular, such compounds may have the following advantages: the compounds are more effective in vivo and / or exhibit favorable properties.

[0521] Without wishing to be bound by theory, the compounds described herein are believed to be potent agonists of the [beta]2-adrenergic receptor, which allows for increased glucose uptake in skeletal muscle cells.

[0522] In addition, the compounds described herein are believed to be agonists of the β2-adrenergic receptor without inducing cAMP production (or with only minimal effect). It is believed that this may increase glucose uptake in skeletal muscle cells with a lower level of side effects than other treatments. In addition, it is believed that combining the compounds described herein with therapeutic agents capable of lowering blood glucose levels may provide an effective combination therapy.

[0523] Additionally, the compounds of the invention may be particularly anaesthetic (eg, anabolic), ie, the process by which a therapeutic agent is biotransformed to aid excretion.

[0524] Examples

[0525] The present invention is illustrated by way of the following examples.

[0526] Unless otherwise stated, chemicals and reagents were purchased from commercial suppliers and used as received. All reactions involving moisture-sensitive reagents were performed under a positive pressure of nitrogen or argon in an oven or flame-dried glassware.

[0527] abbreviation

[0528] The abbreviations used herein will be known to those skilled in the art. Specifically, the following abbreviations may be used herein.

[0529] AcOH Acetic acid

[0530] aq water content

[0531] atm atmospheric pressure

[0532] Boc2O Di-tert-butyl dicarbonate

[0533] DIPEA N,N-Diisopropylethylamine

[0534] DMAP 4-dimethylaminopyridine

[0535] DMF Dimethylformamide

[0536] DMSO Dimethyl sulfoxide

[0537] eq equivalent

[0538] EtOAc Ethyl acetate

[0539] HPLC High Performance Liquid Chromatography

[0540] iPrOH Isopropyl alcohol

[0541] MeCN Acetonitrile

[0542] MeOH Methanol

[0543] Pd-C Palladium Carbon

[0544] rt room temperature

[0545] sat saturated

[0546] TFA Trifluoroacetic acid

[0547] THF Tetrahydrofuran

[0548] Example compounds

[0549] If there is a discrepancy between the nomenclature and the structure of a compound, as depicted in diagrammatic form, the latter governs (unless contradicted by any experimental details that may be given and / or unless clear from the context).

[0550] Example 1: 2-(Butylamino)-1-(3,5-difluorophenyl)ethan-1-ol

[0551]

[0552] (a) 2-(3,5-difluorophenyl)ethylene oxide

[0553]

[0554] A solution of trimethylsulfonium iodide (413mg, 2.02mmol) in DMSO (6mL) was added dropwise to a suspension of ice-cooled NaH (2.1mmol, prepared by washing with Et2O from 84mg of mineral oil containing 60% NaH) in THF (6mL). The ice-cooled mixture was stirred for 30 minutes, and a solution of 3,5-difluorobenzaldehyde (250mg, 1.76mmol) in THF (2.45mL) was slowly added. The mixture was stirred for 20 minutes, the cooling bath was removed, and stirring was continued at room temperature for 2 hours. The mixture was poured onto ice and extracted with Et2O. The combined extracts were washed with water, brine, dried (Na2SO4) and concentrated to obtain the subtitle compound (257mg, 1.65mmol, 94%), which was used in the next step without any further purification.

[0555] (b) 2-(Butylamino)-1-(3,5-difluorophenyl)ethan-1-ol

[0556] A mixture of 2-(3,5-difluorophenyl)oxirane (100 mg, 0.64 mmol), n-butylamine (158 μL, 1.60 mmol) and MeOH (1 mL) was stirred at reflux for 6 hours. The mixture was concentrated and the residue was purified by chromatography to give the title compound (98 mg, 0.43 mmol, 67%).

[0557] 1H NMR (300MHz, CDCl3): δ6.97–6.84(m,2H),6.69(tt,J=8.8,2.4Hz,1H),4.64(dd,J=8.7,3.6Hz, 1H), 2.92(dd,J=12.0,3.6Hz,1H),2.72–2.55(m,3H),1.52–1.27(m,4H),0.92(t,J=7.2Hz,3H).

[0558] Example 2: 2-(Butylamino)-1-(3,4-difluorophenyl)ethan-1-ol

[0559]

[0560] (a) 2-(Benzyl(butyl)amino)-1-(3,4-difluorophenyl)ethan-1-ol

[0561]

[0562] The sub-title compound was prepared according to the procedures in Example 1, steps (a) and (b) from 3,4-difluorobenzaldehyde and N-benzylbutylamine.

[0563] (b) 2-(Butylamino)-1-(3,4-difluorophenyl)ethan-1-ol

[0564] A mixture of 2-(benzyl(butyl)amino)-1-(3,4-difluorophenyl)ethan-1-ol (70 mg, 0.22 mmol), 10% Pd-C (23.3 mg, 0.022 mmol) and AcOH (2 mL) was hydrogenated at room temperature at 6.5 atm for 2 hours, filtered through celite and concentrated. NaHCO (saturated aqueous solution) was added to the residue extracted with EtO. The combined extracts were washed with water, brine, dried (NaSO), concentrated and purified by chromatography to give the title compound (30 mg, 0.13 mmol, 60%).

[0565] 1 H NMR (400 MHz, CDCl3): δ 7.24-7.19 (m, 1H), 7.15-7.04 (m, 2H), 4.67 (dd, J = 9.2, 3.5 Hz, 1H), 2.89 (dd, J = 12.2, 3.6 Hz, 1H), 2.86-2.69 (br s, 2H overlap), 2.74-2.58 (m, 3H), 1.54-1.42 (m, 2H), 1.35 (h, J = 7.2 Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H)

[0566] Example 3: (R)-2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0567]

[0568] (a) tert-Butyl (2-(4-fluorophenyl)-2-oxoethyl)carbamate

[0569]

[0570] At 0 ° C, a solution of 4-fluorobenzoyl bromide (300 mg, 1.38 mmol) in CH2Cl2 (4 mL) was added to a mixture of n-butylamine (205 μL, 2.07 mmol), DIPEA (239 μL, 1.38 mmol) and CH2Cl2 (1 mL) in 10 minutes. The mixture was stirred at room temperature for 2 hours, Boc2O (3.4 mL, 15 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was washed with H2O and brine, dried over Na2SO4 and filtered. The filtrate was concentrated and purified by chromatography to obtain the subtitle compound (270 mg, 0.87 mmol, 63%).

[0571] (b) (R)-butyl (2-(4-fluorophenyl)-2-hydroxyethyl) carbamate tert-butyl ester

[0572]

[0573] (S,S)-N-(p-Toluenesulfonyl)-1,2-diphenylethylenediamine(chloro)(p-isopropyltoluene)ruthenium(II) (16.4 mg, 0.026 mmol) (prepared as described in Kawamato, AM and Wills, M., J. Chem. Soc. Perkin 1, 1916 (2001)) was added to a formic acid / Et3N mixture (5:2, 2 mL) of tert-butyl butyl(2-(4-fluorophenyl)-2-oxoethyl)carbamate (200 mg, 0.65 mmol). The mixture was stirred at room temperature for 64 hours, and H2O (15 mL) and CH2Cl2 (15 mL) were added. The layers were separated and the aqueous layer was extracted with CH2Cl2. The combined organic phases were washed with H2O, brine, dried over Na2SO4 and concentrated. The residue was purified by chromatography to give the sub-title compound (164 mg, 0.53 mmol, 82%).

[0574] (c) (R)-2-(Butylamino)-1-(4-fluorophenyl)ethan-1-ol

[0575]

[0576] A solution of NaOH (421 mg, 10.5 mmol) in water (1.5 mL) was added to a solution of (R)-butyl (2-(4-fluorophenyl)-2-hydroxyethyl) carbamate (164 mg, 0.53 mmol) in EtOH (1.5 mL). The mixture was heated at 120 ° C for 16 hours in a sealed vial. After cooling, the pH was adjusted to 6 with HCl (1 M, aqueous solution), and the mixture was extracted with EtOAc. The combined extracts were dried (Na2SO4), concentrated and purified by chromatography to give the title compound (64 mg, 0.30 mmol, 58%).

[0577] 1 H NMR (400MHz, CDCl3): δ7.41–7.36(m,2H),7.04–6.98(m,2H),5.40(dd,J=10.5,2.6Hz,1H),3.19(dd,J=12.5,2.6Hz, 1H), 3.09 (dd, J=12.5, 10.5Hz, 1H), 3.06–3.01 (m, 2H), 1.90–1.82 (m, 2H), 1.45–1.36 (m, 2H), 0.91 (t, J=7.4Hz, 3H).

[0578] Example 4: (R)-2-(Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0579]

[0580] The title compound was prepared according to the procedure in Example 3 from 3-fluorobenzoyl bromide.

[0581] 1 H NMR (400MHz, CDCl3): δ7.33–7.26(m,1H),7.14–7.11(m,2H),6.98–6.93(m,1H),7.00–6.82(br s,3H),4.93(dd,J=9.9,3.1Hz,1H),2.99(dd,J=12.3,3.1Hz,1H),2.88–2.72(m ,3H),1.98(s,3H),1.63–1.56(m,2H),1.40–1.31(m,2H),0.91(t,J=7.3Hz,3H).

[0582] Example 5: (R)-2-(tert-butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0583]

[0584] (a) (R)-2-Bromo-1-(3-fluorophenyl)ethan-1-ol

[0585]

[0586] Borane (1M in THF, 0.68mL, 0.68mmol) is added dropwise to a mixture of (R)-2-methyl-CBS-oxazaborane (1M in toluene, 0.85mL, 0.85mmol) and THF (0.8mL) at room temperature. The mixture is stirred at room temperature for 15 minutes, and a solution of 3-fluorobenzoyl bromide (185mg, 0.85mmol) in THF (1.9mL) is added dropwise (0.09mL / point). After 6 hours at room temperature, MeOH (10mL) is added. The mixture is stirred for 30 minutes and concentrated. Purified by chromatography, so as to obtain the subtitle compound (150mg, 0.68mmol, 80%).

[0587] (b) (R)-2-(3-Fluorophenyl)oxirane

[0588]

[0589] At room temperature KCO (137 mg, 0.99 mol) was added to a MeOH mixture (6.8 mL) of (R)-2-bromo-1-(3-fluorophenyl) ethyl-1-ol (145 mg, 0.66 mmol). The mixture was stirred for 30 minutes, filtered and concentrated. CHCl was used to extract the residue. The combined extracts were concentrated to obtain the sub-title compound (70 mg, 0.51 mmol, 77%), which was used in the next step without further purification.

[0590] (c) (R)-2-(tert-Butylamino)-1-(3-fluorophenyl)ethan-1-ol

[0591]

[0592] A mixture of (R)-2-(3-fluorophenyl)oxirane (30 mg, 0.22 mmol), tert-butylamine (66 mg, 0.90 mmol) and MeOH (0.2 mL) was stirred at reflux for 16 hours, cooled and concentrated, and dissolved in Et2O. Et2O / pentane (1:3) was added, and the solution was kept at -20°C overnight. The solid formed was collected to give the title compound (25 mg, 0.12 mmol, 54%).

[0593] 1H NMR (400MHz, CDCl3): δ7.33–7.26(m,1H),7.14–7.09(m,2H),6.98–6.93(m,1H),4.57(dd,J =8.4, 3.6Hz, 1H), 2.92 (dd, J = 12.0, 4.0Hz, 1H), 2.55 (dd, J = 12.0, 8.4Hz, 1H), 1.10 (s, 9H).

[0594] Example 6: 1-(4-amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0595]

[0596] (a) 1-(4-amino-3,5-difluorophenyl)ethan-1-ol

[0597]

[0598] PdCl2(MeCN)2 (102 mg, 0.39 mmol) was added to a mixture of 3,6-difluoro-4-iodoaniline (2.00 g, 7.84 mmol), ZnO (830 mg, 10.2 mol), tetrabutylammonium bromide (3.79 g, 11.8 mmol), Et3N (0.37 mL, 2.67 mmol) and DMSO (20 mL) at room temperature. The mixture was stirred at 100 ° C for 16 hours under ambient atmosphere. Another portion of Et3N (0.37 mL, 2.67 mmol) was added and heating was continued for 3 hours. The mixture was cooled, diluted with Et2O and washed with H2O. The phases were separated and the aqueous layer was extracted with Et2O. The combined organic phases were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by chromatography to give the subtitle compound (270 mg, 1.58 mmol, 20%)

[0599] (b) 1-(4-amino-3,5-difluorophenyl)-2-bromoethan-1-one

[0600]

[0601] A mixture of bromine (0.16mL, 3.15mmol) and CHCl3(10mL) was added to a mixture of 1-(4-amino-3,5-difluorophenyl)ethan-1-one (270mg, 1.58mmol) and CHCl3(15mL) at reflux within 30 minutes. After refluxing for 15 minutes, the mixture was cooled and concentrated. The residue was dissolved in THF(6mL) and cooled in an ice bath. A solution of diethyl phosphite (0.22mL, 1.74mmol) and Et3N(0.24mL, 1.74mmol) in THF(9mL) was slowly added. The mixture was slowly brought to room temperature, stirred at room temperature for 17 hours and concentrated. Ice / water was added to the residue, and the mixture was extracted with EtOAc. The combined extracts were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by chromatography to obtain the subtitle compound (250mg, 1.00mmol, 63%).

[0602] (c) 1-(4-Amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-one hydrochloride

[0603]

[0604] To a solution of 1-(4-amino-3,5-difluorophenyl)-2-bromoeth-1-one (100 mg, 0.40 mmol) in CHCl (1 mL) was added DIPEA (83 μL, 0.48 mmol) followed by n-butylamine (47 μL, 0.48 mmol) at room temperature. The mixture was heated at 75 °C for 1 hour and cooled to 40 to 50 °C while adding HCl (1 M in EtO, 560 μL, 0.56 mmol). The mixture was cooled to room temperature and the solid was collected to give the subtitle compound (44 mg, 0.16 mmol, 40%), which was used in the next step without further purification.

[0605] (d) 1-(4-amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0606]

[0607] NaOH (1M, about 0.15mL) was added to a mixture of 1-(4-amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-one hydrochloride (40mg, 0.14mmol), MeOH (0.2mL) and H2O (0.3mL) to adjust the pH to 9. A solution of NaBH4 (10.9mg, 0.29mmol) in H2O was added dropwise, and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to remove MeOH. Water was added, and the mixture was extracted with CH2Cl2. The combined extracts were washed with brine, dried over Na2SO4 and concentrated. The residue was dissolved in Et2O (1mL). Pentane (5mL) was added and the solid was collected to give the subtitle compound (20mg, 0.082mmol, 57%)

[0608] 1 H NMR (400 MHz, CDCl3): δ 6.89-6.80 (m, 2H), 4.54 (dd, J = 8.8, 3.4 Hz, 1H), 3.75-3.60 (br s, 2H), 2.84 (dd, J = 12.1, 3.4 Hz, 1H), 2.70-2.57 (m, 3H), 2.73-2.03 (br s, 2H, overlapping), 1.51-1.41 (m, 2H), 1.40-1.29 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H).

[0609] Example 7: 1-(3-amino-2,4-difluorophenyl)-2-(butylamino)ethan-1-ol

[0610]

[0611] (a) N-(2,6-difluoro-3-methylphenyl)acetamide

[0612]

[0613] A mixture of 2,6-difluoro-3-methylaniline (4 g, 27.9 mmol) and acetic anhydride (5.3 mL) was heated at 60 °C for 2 hours. Water was added and the mixture was extracted with CH2Cl2. The combined extracts were washed with brine, dried over Na2SO4 and concentrated. Purification by chromatography gave the subtitle compound (5.1 g, 27.5 mmol, 99%).

[0614] (b) 3-Acetylamino-2,4-difluorobenzoic acid

[0615]

[0616] KMnO4 (10.7 g, 67.7 mmol) was carefully added to a mixture of N-(2,6-difluoro-3-methylphenyl)acetamide (2.5 g, 13.5 mmol), pyridine (20 mL) and H2O (70 mL) at 70 °C. The mixture was heated to reflux for 10 hours, filtered through a pad of celite while hot, and the pad was washed with hot H2O. The filtrate was cooled to room temperature, concentrated and carefully acidified with HCl (aqueous solution, 6 M). The mixture was cooled in an ice bath and filtered. The solid was washed with cold H2O, dried and purified by chromatography to give the subtitle compound (2.1 g, 9.76 mmol, 72%).

[0617] (c) N-(3-(2-bromoacetyl)-2,6-difluorophenyl)acetamide

[0618]

[0619] A mixture of 3-acetylamino-2,4-difluorobenzoic acid (1.1 g, 5.11 mmol), SOCl2 (8 mL) and CH2Cl2 (20 mL) was stirred at room temperature for 2 hours, concentrated and dried in vacuo. The residue was dissolved in CH2Cl2 (60 mL) and trimethylsilyldiazomethane (5.1 mL, 10.2 mmol) was added dropwise at 0 ° C. The mixture was allowed to reach room temperature within 4 hours and cooled to 0 ° C. HBr (33% in AcOH solution, 2.8 mL) was added dropwise. The mixture was allowed to reach room temperature within 2.5 hours, diluted with CH2Cl2, and washed with NaHCO3 (saturated aqueous solution) and NH4Cl (saturated aqueous solution), and dried and concentrated over MgSO4 to obtain the subtitle compound of quantitative yield, which was used in the next step without further purification.

[0620] (d) 1-(3-amino-2,4-difluorophenyl)-2-bromoethan-1-one

[0621]

[0622] HBr (aqueous solution, 48%, 0.05 mL) was added to N-(3-(2-bromoacetyl)-2,6-difluorophenyl)acetamide (70 mg, 0.24 mmol) at room temperature. The mixture was heated to 100°C and stirred at that temperature for 40 minutes, cooled and poured into H2O. The mixture was extracted with EtOAc and the combined extracts were washed with H2O, NaHCO3 (saturated aqueous solution), brine and dried over MgSO4. Concentration gave the subtitle compound (50 mg, 0.20 mmol, 83%).

[0623] (e) 2,6-Difluoro-3-(2-oxiranyl)aniline

[0624]

[0625] At 0°C, NaBH4 (3.78 mg, 0.10 mmol) was added to a mixture of 1-(3-amino-2,4-difluorophenyl)-2-bromoethyl-1-one (50 mg, 0.20 mmol). The cooling bath was removed and the mixture was stirred at room temperature for 1 hour. MeOH (1 mL) and K2CO3 (41.5 mg, 0.30 mmol) were added and the mixture was stirred at room temperature for 3 hours and concentrated. Water was added to the residue and the mixture was extracted with CH2Cl2, and the combined extracts were washed with H2O, brine, dried over MgSO4, and filtered through neutral alumina. Concentration gave the subtitle compound (20 mg, 0.12 mmol, 58%).

[0626] (f) 1-(3-amino-2,4-difluorophenyl)-2-(butylamino)ethan-1-ol

[0627]

[0628] A mixture of 2,6-difluoro-3-(oxiran-2-yl)aniline (30 mg, 0.18 mmol), n-butylamine (12.8 mg, 0.18 mmol) and EtOH (0.9 mL) was stirred at 50° C. for 18 hours. The mixture was concentrated and the residue was purified by chromatography to give the title compound (22 mg, 0.09 mmol, 51%).

[0629] 1 H NMR (400MHz, CDCl3): δ6.90–6.72(m,2H),4.97(dd,J=8.8,3.6Hz,1H),3.70(s,2H),2.9 4(dd,J=13.0,3.6Hz,1H),2.72–2.58(m,3H),1.52–1.30(m,4H),0.92(t,J=7.2Hz,3H).

[0630] Example 8: N-(3-(2-(Butylamino)-1-hydroxyethyl)-2,6-difluorophenyl)acetamide

[0631]

[0632] The title compound was prepared according to the procedures in Example 7, steps (e) and (f) from N-(3-(2-bromoacetyl)-2,6-difluorophenyl)acetamide (see Example 7, step (c)).

[0633] 1H NMR (400MHz, THF-d8): δ8.69(br s,1H),7.41(q,J=8.2Hz,1H),6.92(t,J=8.8Hz,1H),4.93(dd,J=8.6,3.2Hz,1H),2.76(ddd,J=8.4,4.8,3.6Hz 1H), 2.66–2.56 (m, 3H), 2.04 (s, 3H), 1.48–1.29 (m, 4H), 0.90 (t, J = 7.2Hz, 3H).

[0634] Example 9: 1-(4-amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0635]

[0636] (a) 3-Amino-2-fluoroacetophenone

[0637]

[0638] At 55 ° C, iron powder (595mg, 10.6mmol) was added to the solution of 2-fluoro-3-nitroacetophenone, followed by H2O (1.2mL) containing NH4Cl (570mg, 10.6mmol). The mixture was heated to reflux for 2.5 hours, cooled to room temperature, and filtered through diatomaceous earth. NaHCO3 (saturated aqueous solution) was added to the filtrate, and the filtrate was then extracted with EtOAc. The combined extracts were washed with brine, dried over MgSO4 and concentrated. The residue was extracted with hexane, and the extract was concentrated. The residue was extracted with hexane / Et2O (10: 1), and the extract was concentrated to obtain the subtitle compound (350mg, 2.28mmol, 84%).

[0639] (b) N-(3-Acetyl-2-fluorophenyl)acetamide

[0640]

[0641] The sub-title compound was prepared according to the procedure in Example 7, step (a) from 3-amino-2-fluoroacetophenone.

[0642] (c) N-(3-(2-bromoacetyl)-2,6-difluorophenyl)acetamide

[0643]

[0644] CuBr (652 mg, 2.92 mmol) was added to a solution of N-(3-acetyl-2-fluorophenyl)acetamide (380 mg, 1.95 mmol) in EtOAc (4.8 mL) at room temperature. The mixture was heated to reflux for 20 hours, cooled and extracted with EtOAc. The combined extracts were washed with brine, dried over MgSO4, filtered through neutral alumina and concentrated. The residue was purified by chromatography to give the subtitle compound (135 mg, 0.49 mmol, 25%).

[0645] (d) 1-(4-amino-3,5-difluorophenyl)-2-(butylamino)ethan-1-ol

[0646] The title compound was prepared according to the procedures of Example 7, steps (d), (e) and (f) from N-(3-(2-bromoacetyl)-2,6-difluorophenyl)acetamide.

[0647] 1 H NMR (400MHz, CDCl3): δ6.93 (dd, J=11.0, 8.2Hz, 1H), 6.82 (dd, J=8.6, 2.2Hz, 1H), 6.67–6.64 (m, 1H), 4.58 (dd, J=9.0 ,3.8Hz,1H),3.71(s,2H),2.86(dd,J=12.0,3.6Hz,1H),2.70–2.60(m,3H),1.51–1.30(m,4H),0.92(t,J=7.4Hz,3H).

[0648] Examples 10 and 11: (R)-1-(4-fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol and

[0649] (R)-1-(4-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0650]

[0651] (a) tert-Butyl (2-(4-fluorophenyl)-2-oxoethyl)(pentan-2-yl)carbamate

[0652]

[0653] At 0 ° C, a solution of 4-fluorobenzoyl bromide (500 mg, 2.31 mmol) in CH2Cl2 (6.6 mL) was added to a solution of 2-aminopentane (301 mg, 3.46 mmol) and DIPEA (298 mg, 2.31 mmol) in CH2Cl2 (1.6 mL) over 10 minutes. The cooling bath was removed and the mixture was stirred at room temperature for 2 hours. A solution of Boc2O (1.26 g, 5.76 mmol) in CH2Cl2 (6 mL) was added and the mixture was stirred at room temperature for 2 hours, washed with H2O, brine and dried over Na2SO4. Concentrated and purified by chromatography to give the subtitle compound (520 mg, 1.61 mmol, 70%).

[0654] (b) (R)-1-(4-fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol and

[0655] (R)-1-(4-Fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0656] Using the procedure in Example 3, step (b), followed by chromatography and hydrolysis of each Boc protected intermediate according to the procedure in Example 3, step (c), the title compounds were obtained.

[0657] 1 H NMR (400MHz, CDCl3): δ7.34(dd,J=8.4,5.6Hz,2H),7.03(t,J=8.4Hz,2H),4.61(dd,J=9.4,3.4Hz,1H),2.91 (dd,J=12.0,3.6Hz,1H),2.69–2.59(m,2H),1.47–1.28(m,4H),1.06(d,J=6.0Hz,3H),0.91(t,J=6.8Hz,3H).

[0658] as well as

[0659] 7.42(dd,J=8.4,5.6Hz,2H),7.03(t,J=8.8Hz,2H),5.40(dd,J=10.4,2.4Hz,1H),3.28–3.21(m,2H),2 .99(t,J=11.2Hz,1H),1.94–1.85(m,1H),1.72–1.63(m,1H),1.51–1.34(m,5H),0.91(t,J=7.4Hz,3H).

[0660] Examples 12 and 13: (R)-1-(3-fluorophenyl)-2-(((R)-pentan-2-yl)amino)ethan-1-ol and (R)-1-(3-fluorophenyl)-2-(((S)-pentan-2-yl)amino)ethan-1-ol

[0661]

[0662] According to Examples 10 and 11, the title compound was prepared from 3-fluorobenzoyl bromide.

[0663] 1 H NMR (400MHz, CDCl3): δ7.33–7.26(m,1H),7.14–7.09(m,2H),7.00–6.90(m,1H),4.66(dd,J=8.8,3.6Hz,1H ),2.97–2.92(m,1H),2.72–2.62(m,3H),1.47–1.26(m,4H),1.07(dd,J=6.4,1.2Hz,3H),0.93–0.89(m,3H).

[0664] as well as

[0665] 7.33–7.27(m,1H),7.21–7.18(m,2H),7.00–6.96(m,1H),5.40(dd,J=10.4,2.4Hz,1H),3.31–3.20(m,2H) ,2.98(t,J=11.4,Hz,1H),1.93–1.85(m,1H),1.72–1.62(m,1H),1.50–1.33(m,5H),0.91(t,J=7.4Hz,3H).

[0666] Example 14: (R) 1-(3-fluorophenyl)-2-((2-methylpentan-2-yl)amino)ethan-1-ol

[0667]

[0668] A mixture of (R)-2-(3-fluorophenyl)oxirane (40 mg, 0.29 mmol), 2-methylpentan-2-amine hydrochloride (80 mg, 0.58 mmol), DIPEA (0.1 mL, 0.58 mmol) and MeOH (0.3 mL) was stirred at reflux for 16 hours, cooled and concentrated. The residue was purified by chromatography and crystallized from EtO / hexane (1:4) to give the title compound (10 mg, 0.042 mmol, 14%).

[0669] 1H NMR (400MHz, CDCl3): δ7.32-7.27(m,1H),7.19–7.09(m,2H),6.98-6.93(m,1H),4.85(dd,J=9.2,3.2Hz,1H),4.07(br s,1H),2.99(dd,J=11.8,3.4Hz,1H),2.66(dd,J=12.2,9.4Hz,1H),1.48–1.27(m,4H),1.18(d,J=3.6Hz,6H),0.91(t,J=7.2Hz,3H).

[0670] Example 15: (R)-2-(tert-butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0671]

[0672] (a) 2-Bromo-1-(2,3-difluorophenyl)ethan-1-one

[0673]

[0674] At room temperature, trimethylphenylammonium tribromide (1.59 g, 4.22 mmol) was added in batches to a stirred solution of 2,3-difluoroacetophenone (0.60 g, 3.84 mmol) in CH2Cl2 (10 mL). The mixture was stirred at room temperature overnight, diluted with CH2Cl2 and poured into water. The layers were separated and the aqueous phase was extracted with CH2Cl2. The combined extracts were dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography to obtain the subtitle compound (0.80 g, 3.40 mmol, 89%).

[0675] (b) 2-Chloro-1-(2,3-difluorophenyl)ethan-1-one

[0676]

[0677] NaCl (saturated aqueous solution, 4mL) was added to a solution of 2-bromo-1-(2,3-difluorophenyl)ethan-1-one (600mg, 2.55mmol) in THF (10mL) at room temperature. The mixture was heated at 70 ° C for 16 hours in a sealed tube and then cooled. The mixture was diluted with EtOAc (100mL) and brine, and the layers were separated. The aqueous phase was extracted with EtOAc, and the combined organic phases were dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography to obtain the subtitle compound (350mg, 1.84mmol, 72%).

[0678] (c) (R)-2-Chloro-1-(2,3-difluorophenyl)ethan-1-ol

[0679]

[0680] RhClCp*[(1S,2S)-p-TsNCH(C6H5)CH(C6H5)NH2] / HCl.Et3N (20.4 mg, 26 μmol) prepared from dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer, (1S,2S)-(+)-N-(4-tosyl)-1,2-diphenylethylenediamine and Et3N as described in WO 2008 / 054155 was added to a mixture of 2-chloro-1-(2,3-difluorophenyl)ethan-1-one (500 mg, 2.62 mmol) in THF (10 mL). Formic acid / Et3N (5:2, 1 mL) was added and the mixture was stirred at room temperature for 80 minutes. The mixture was diluted with EtOAc, washed twice with H2O, dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography to give the sub-title compound (420 mg, 2.18 mmol, 83%, ee = 88%).

[0681] (d) (R)-2-(2,3-Difluorophenyl)oxirane

[0682]

[0683] NaOH (aqueous solution, 1 M, 5.9 mL, 5.9 mmol) was added dropwise to a solution of (R)-2-chloro-1-(2,3-difluorophenyl)ethan-1-ol (380 mg, 1.97) in iPrOH (4 mL) at 0 °C. The mixture was diluted with Et2O and the layers were separated. The aqueous phase was extracted with Et2O and the combined organic phases were dried (Na2SO4), filtered and carefully concentrated. The product was volatile, the material was an approximately 1:1 mixture of the subtitle compound and iPrOH, and the material was used in the next step without further purification.

[0684] (e)(R)-2-(tert-Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0685]

[0686] A mixture of (R)-2-(2,3-difluorophenyl)oxirane (200 mg, 1.28 mmol, containing iPrOH) and tert-butylamine (0.30 mL, 2.8 mmol) was stirred at 70° C. for 16 hours, cooled and concentrated. The residue was treated with Et2O / pentane (3+10 mL) at -20° C., the solid was collected, and washed with cold Et2O / pentane to give the title compound (135 mg, 0.59 mmol, 46%, ee=88%).

[0687] 1H NMR (400MHz, CDCl3): δ7.35–7.28(m,1H),7.12–7.00(m,2H),4.91(dd,J=8.4,3.7Hz,1H),3.00(ddd,J=12.0,3.7,1.1Hz,1H),3.0-2.0(br s 2H), 2.55 (ddd, J=12.1, 8.4, 0.7Hz, 1H), 1.11 (s, 9H).

[0688] Example 16: (R)-2-(Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol

[0689]

[0690] A mixture of (R)-2-(2,3-difluorophenyl)oxirane (200 mg, 1.28 mmol, containing iPrOH) and n-butylamine (2.5 mL, 25.6 mmol) was heated at 100° C. for 1 hour under microwave irradiation. The residue was concentrated and purified by chromatography to give the title compound (220 mg, 0.96 mmol, 75%).

[0691] 1 H-NMR (400MHz, CDCl3): δ7.34-7.27(m,1H),7.12–7.00(m,2H),5.01(dd,J=8.8,3.5Hz,1H),3.03–2.92(m,1H),2.90–2.40(br s,2H),2.74-2.57(m,3H),1.54-1.41(m,2H),1.41-1.27(m,2H),0.91(t,J=7.3Hz,3H).

[0692] Example 17: (R)-2-(tert-Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0693]

[0694] The title compound was prepared according to the procedure in Example 15, step (f) from (R)-2-(2-fluorophenyl)oxirane and tert-butylamine.

[0695] 1 H NMR (300MHz, CDCl3): δ7.56(m,1H),7.19–7.28(m,1H),7.16(m,1H),6.97–7.05(ddd,J=10.5,8.1,1.3Hz,1H),4.92(dd ,J=8.5,3.8Hz,1H),3.00(ddd,J=11.9,3.8,0.9Hz,1H),2.57(dd,J=11.7,8.5Hz,1H),1.85–2.57(bs,2H),1.12(s,9H)

[0696] Example 18: (R)-2-(Butylamino)-1-(2-fluorophenyl)ethan-1-ol

[0697]

[0698] The title compound was prepared according to the procedure in Example 16 from (R)-2-(2-fluorophenyl)oxirane and n-butylamine.

[0699] 1 H NMR (300MHz, CDCl3): δ7.60–7.51(m,1H),7.29–7.20(m,1H),7.19–7.12(m,1H),7.00(ddd,J=10.6,8.1,1.3Hz,1H),5.02(dd,J=8.8,3.6Hz, 1H), 2.99(ddd,J=12.2,3.6,1.1Hz,1H),2.80–2.54(m,3H),2.52–2.09(bs,2H),1.54–1.42(m,2H),1.42–1.30(m,2H),0.92(t,J=7.2Hz,3H).

[0700] Example 19: (R)-2-(2-(tert-butylamino)-1-hydroxyethyl)-5-fluorophenol acetate

[0701]

[0702] (a) 1-(2-(Benzyloxy)-4-fluorophenyl)ethan-1-one

[0703]

[0704] A mixture of 4-fluoro-2-hydroxyacetophenone (319 mg, 2.07 mmol), benzyl bromide (0.29 mL, 2.48 mmol), KCO (572 mg, 4.14 mmol) and acetone (12 mL) was stirred at room temperature for 24 hours and filtered. The filtrate was concentrated and the residue was purified by chromatography to give the subtitle compound (501 mg, 2.05 mmol, 99%).

[0705] (b) 1-(2-(Benzyloxy)-4-fluorophenyl)-2-bromoethan-1-one

[0706]

[0707] At room temperature, bromine (0.12mL, 2.30mmol) was added in batches to a mixture of Et2O (20mL) of 1-(2-(benzyloxy)-4-fluorophenyl)ethan-1-one (562mg, 2.30mmol). After 30 minutes, another portion of bromine (0.06mL, 1.15mmol) was added and the mixture was stirred at room temperature for 90 minutes. The mixture was concentrated and THF (5mL) was added. The mixture was cooled in an ice bath and a mixture of diethyl phosphite (0.30mL, 2.30mmol) and Et3N (0.32mL, 2.30mmol) was added. The ice bath was removed and the mixture was stirred at room temperature for 60 minutes. Ice was added to the mixture and the mixture was stirred overnight. The mixture was diluted with CH2Cl2 and each phase was separated. The aqueous phase was extracted with CH2Cl2 and the combined organic phase was dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography to give the sub-title compound (700 mg, 2.17 mmol, 94%).

[0708] (c) (R)-1-(2-(Benzyloxy)-4-fluorophenyl)-2-bromoethan-1-ol

[0709]

[0710] The sub-title compound was prepared according to the procedure in Example 5, step (a) from 1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethan-1-one.

[0711] (d) (R)-2-(2-(Benzyloxy)-4-fluorophenyl)oxirane

[0712]

[0713] The sub-title compound was prepared according to the procedure in Example 5, step (b) from (R)-1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethan-1-ol.

[0714] (e) (R)-1-(2-(Benzyloxy)-4-fluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0715]

[0716] A mixture of (R)-2-(2-(benzyloxy)-4-fluorophenyl)oxirane (190 mg, 0.78 mmol), n-butylamine (0.180 mL, 1.71 mmol) and MeOH (0.6 mL) was stirred at 70° C. for 3 hours. The mixture was concentrated and the residue was purified by chromatography to give the subtitle compound (135 mg, 0.42 mmol, 55%).

[0717] (f)(R)-2-(2-(tert-Butylamino)-1-hydroxyethyl)-5-fluorophenol acetate

[0718]

[0719] A mixture of (R)-1-(2-(benzyloxy)-4-fluorophenyl)-2-(tert-butylamino)ethan-1-ol (157 mg, 0.49 mmol), Pd-C (10%, 52.6 mg, 0.05 mmol) and AcOH (4 mL) was hydrogenated at 6 bar for 2 hours. The mixture was filtered through celite, concentrated and purified by chromatography. The material was dissolved in AcOH (1%) in MeOH and Et2O was added. The mixture was kept at -20°C for 2 days and the solid was collected and washed with Et2O to give the title compound (60 mg, 0.21 mmol, 42%).

[0720] 1 H NMR (400MHz, D2O): δ7.40(dd,J=8.6,6.7Hz,1H),6.84–6.65(m,2H),5.21(dd,J=9.4,3.2Hz ,1H),3.37(dd,J=12.8,3.2Hz,1H),3.25(dd,J=12.7,9.4Hz,1H),1.94(s,0H),1.41(s,9H).

[0721] Example 20: (R)-2-(2-(Butylamino)-1-hydroxyethyl)-5-fluorophenol acetate

[0722]

[0723] (a) (R)-(1-(2-(Benzyloxy)-4-fluorophenyl)-2-bromoethoxy)triethylsilane

[0724]

[0725] Triethylsilyl chloride (0.12 mL, 0.73 mmol) was added in one portion to a mixture of (R)-1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethan-1-ol (215 mg, 0.66 mmol) (see step (c) of Example 19), imidazole (58.5 mg (0.86 mmol) and DMF (5 mL) at 5°C. The temperature was brought to 15°C and the mixture was stirred at that temperature for 1 hour. The mixture was diluted with petroleum ether, washed 3 times with H2O, dried (Na2SO4), filtered and concentrated to give the subtitle compound (270 mg, 0.61 mmol, 93%).

[0726] (b) (R)-N-(2-(2-(Benzyloxy)-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)butan-1-amine

[0727]

[0728] A mixture of (R)-(1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethoxy)triethylsilane (270 mg, 0.61 mmol), n-butylamine (0.30 mL, 3.07 mmol) and dioxane (2 mL) was heated at 80° C. for 16 h. Another portion of n-butylamine (0.30 mL, 3.07 mmol) was added and the mixture was heated at 105° C. for 48 h. The mixture was allowed to cool and H2O and Et2O were added. The organic layer was collected and washed 3 times with NH4Cl (saturated aqueous solution), NaHCO3 (saturated aqueous solution) and brine, dried (Na2SO4), filtered and concentrated. The residue was dissolved in THF (3 mL) and tributylammonium fluoride (1 M in THF, 0.74 mL, 0.74 mmol) was added dropwise at 5° C. The mixture was stirred at 50° C. for 20 min, allowed to cool, and H2O and Et2O were added. The organic layer was collected and washed with H2O (aq., sat.), brine, dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography to give the sub-title compound (94 mg, 0.30 mmol, 48%).

[0729] (c) (R)-2-(2-(Butylamino)-1-hydroxyethyl)-5-fluorophenol acetate

[0730]

[0731] The title compound was prepared according to the procedure in Example 19, step (f) from (R)-1-(2-(benzyloxy)-4-fluorophenyl)-2-(butylamino)ethan-1-ol.

[0732] 1H NMR (400MHz, D2O): δ7.40(dd,J=8.6,6.7Hz,1H),6.80–6.68(m,2H),5.26(dd,J=8.7,3.9Hz,1H),3.38(dd,J=13.0,4.0Hz,1H),3.32 (dd,J=12.9,8.7Hz,1H),3.17–3.09(m,2H),1.94(s,3H),1.71(tt,J=7.9,6.5Hz,2H),1.41(h,J=7.4Hz,2H),0.95(t,J=7.4Hz,3H).

[0733] Example 21: (R)-1-(3-Fluorophenyl)-2-((1-methylcyclobutyl)amino)ethan-1-ol

[0734]

[0735] A mixture of (R)-2-(2-fluorophenyl)oxirane (130 mg, 0.94 mmol), (1-methylcyclobutyl)amine hydrochloride (298 mg, 2.45 mmol), DIPEA (0.33 mL, 1.88 mmol) and iPrOH (0.5 mL) was stirred at 70° C. for 3 hours, cooled and poured into NaHCO (saturated aqueous solution). The mixture was extracted with EtOAc and the combined extracts were dried (NaCO) and concentrated. The residue was purified by chromatography to give the title compound (60 mg, 0.27 mmol, 29%).

[0736] 1 H NMR (400MHz, CDCl3): δ7.30(td,J=8.1,5.9Hz,1H),7.15–7.09(m,2H),6.99–6.92(m,1H),4.66 (dd,J=8.7,3.6Hz,1H),2.90(dd,J=12.1,3.7Hz,1H),2.56(dd,J=12.1,8.7Hz,1H),2.5-2.0(br s,2H),2.03–1.90(m,2H),1.87–1.69(m,4H),1.28(s,3H).

[0737] Example 22: (R)-1-(3-Fluorophenyl)-2-((1-methylcyclopropyl)amino)ethan-1-ol

[0738]

[0739] According to Example 21, the title compound was prepared from (R)-2-(2-fluorophenyl)oxirane and (1-methylcyclopropyl)amine hydrochloride.

[0740] 1 H NMR (300MHz, CDCl3): δ77.35–7.27(m,1H),7.17–7.06(m,2H),6.95(td,J=8.5,2.6Hz,1H),4.60 (dd,J=8.7,3.6Hz,1H),3.08(dd,J=12.1,3.7Hz,1H),2.67(dd,J=12.1,8.7Hz,1H),2.6-2.0(br s,2H),1.25(s,3H),0.70–0.53(m,2H),0.48–0.33(m,2H).

[0741] Example 23: (R)-5-(2-(tert-butylamino)-1-hydroxyethyl)-2-fluorophenol acetate

[0742]

[0743] 1 H NMR (400MHz, D2O): δ7.25–7.14(m,1H),7.12–7.01(m,1H),7.01–6.89(m,1H ), 4.92 (dd, J = 3.2, 9.8Hz, 1H), 3.33–3.14 (m, 2H), 1.92 (s, 3H), 1.40 (s, 9H).

[0744] Example 24: (R)-5-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol acetate

[0745]

[0746] 1 H NMR (400MHz, D2O): δ7.25–7.13(m,1H),7.10–7.01(m,1H),6.98–6.89(m,1H),4.98(dd,J=4.0,9.0Hz,1H),3. 37–3.20(m,2H),3.19–3.03(m,2H),1.92(s,3H),1.75–1.61(m,2H),1.47–1.31(m,2H),0.93(t,J=7.4Hz,3H)

[0747] Example 25: (R)-3-(2-(tert-butylamino)-1-hydroxyethyl)-2-fluorophenol

[0748]

[0749] (a) 1-(3-(Benzyloxy)-2-fluorophenyl)ethan-1-one

[0750]

[0751] The sub-title compound was prepared according to the procedure in Example 20, step (a) from 4-fluoro-2-hydroxyacetophenone and benzyl bromide.

[0752] (b) 1-(3-(Benzyloxy)-2-fluorophenyl)-2-bromoethan-1-one

[0753]

[0754] A mixture of bromine (0.13 mL, 2.45 mmol) and Et2O (2 mL) was added dropwise to a mixture of 1-(3-(benzyloxy)-2-fluorophenyl)ethan-1-one (599 mg, 2.45 mmol) and Et2O (18 mL) at room temperature. After 10 minutes, the mixture was washed with NaHSO4 (saturated aqueous solution) and brine, dried over Na2SO4 and concentrated. The residue was purified by chromatography to give the subtitle compound (600 mg, 1.86 mmol, 76%).

[0755] (c) (R)-1-(3-(Benzyloxy)-2-benzyloxy)-2-bromoethan-1-ol

[0756]

[0757] The sub-title compound was prepared according to the procedure in Example 5, step (a) from 1-(3-(benzyloxy)-2-fluorophenyl)-2-bromoethan-1-one.

[0758] (d) (R)-1-(3-(Benzyloxy)-2-fluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0759]

[0760] NaOH (18.45 mg, 0.46 mmol) was added to a mixture of (R)-1-(3-(benzyloxy)-2-fluorophenyl)-2-bromoeth-1-ol (150 mg, 0.46 mmol), tert-butylamine (0.49 mL, 4.61 mmol) and MeOH (0.2 mL) at room temperature. The mixture was heated at 70° C. for 16 hours, cooled to room temperature, diluted with EtOAc, washed with water, dried over Na SO and concentrated. The residue was purified by chromatography to give the subtitle compound (120 mg, 0.38 mmol, 82%).

[0761] (e)(R)-3-(2-(tert-butylamino)-1-hydroxyethyl)-2-fluorophenol

[0762]

[0763] EtSiH (0.60 mL, 3.78 mmol) was added dropwise to a mixture of (R) 1-(3-(benzyloxy)-2-fluorophenyl)-2-(tert-butylamino)ethan-1-ol (120 mg, 0.38 mmol), Pd-C (10%, 80.5 mg, 0.08 mmol) and MeOH (1 mL) at room temperature. The mixture was stirred at room temperature for 10 minutes, filtered through celite, concentrated and purified by chromatography. The material was triturated with EtO to give the title compound (56 mg, 0.25 mmol, 65%).

[0764] 1 H NMR (400MHz, CD3OD): δ7.04–6.95(m,2H),6.91–6.84(m,1H),5.14(dd,J=9.7,3.3Hz ,1H),3.00(ddd,J=12.0,3.3,0.6Hz,1H),2.91(dd,J=12.0,9.7Hz,1H),1.28(s,9H).

[0765] Example 26: (R)-3-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0766]

[0767] (a) (R)--1-(3-(Benzyloxy)-2-fluorophenyl)-2-(butylamino)ethan-1-ol

[0768]

[0769] The subtitle compound was prepared according to the procedure in Example 25, step (d) from (R)-1-(3-(benzyloxy)-2-fluorophenyl)-2-bromoethan-1-ol.

[0770] (b) (R)-3-(2-(Butylamino)-1-hydroxyethyl)-2-fluorophenol

[0771]

[0772] The title compound was prepared according to the procedure in Example 25, step (e) from (R)-1-(3-(benzyloxy)-2-fluorophenyl)-2-(butylamino)ethan-1-ol.

[0773] 1H NMR (400MHz, CDCl3): δ6.96–6.88(m,2H),6.86–6.81(m,1H),5.07(dd,J=8.9,3.6Hz,1H),4.43(br s,3H),2.92(dd,J=12.1,3.6Hz,1H),2.78(dd,J=12.1,8.8Hz,1H),2.72– 7.59(m,2H),1.54–1.40(m,2H),1.36–1.27(m,2H),0.88(t,J=7.3Hz,3H).

[0774] Example 27: (R)-1-(3-amino-2-fluorophenyl)-2-(tert-butylamino)ethan-1-ol

[0775]

[0776] (a) 2-Fluoro-3-isobutyramidobenzoic acid

[0777]

[0778] A mixture of 3-amino-2-fluorobenzoic acid (2.00 g; 12.9 mmol), isobutyric anhydride (4.3 mL, 25.8 mmol) and CH2Cl2 was heated at 50°C for 2 hours. The mixture was cooled and concentrated. The residue was purified by chromatography to give the subtitle compound (1.24 g, 5.51 mmol, 43%).

[0779] (b) N-(3-(2-bromoacetyl)-2-fluorophenyl)isobutyramide

[0780]

[0781] The mixture of 2-fluoro-3-isobutyramidobenzoic acid (300mg, 1.33mmol), SOCl (1.9mL) and dioxane (3mL) was heated at 50 ℃ for 12 hours, concentrated and dried in vacuo. The residue was dissolved in CH Cl (15mL), and trimethylsilyldiazomethane (1.33mL, 2.66mmol) was added dropwise at 0 ℃. The mixture was stirred at room temperature for 2 hours, and was cooled to 0 ℃. HBr (33% in AcOH solution, 0.91mL) was added dropwise. The mixture was stirred at 0 ℃ for 30 minutes, and stirred at room temperature for 2 hours. NaHCO (saturated aqueous solution) was added until the pH value was about 7. The residue was purified by chromatography to obtain the subtitle compound (0.22mg, 0.73mmol, 55%).

[0782] (c) (R)-N-(3-(2-bromo-1-hydroxyethyl)-2-fluorophenyl)isobutyramide

[0783]

[0784] The sub-title compound was prepared according to the procedure in Example 5, step (a) from N-(3-(2-bromoacetyl)-2-fluorophenyl)isobutyramide.

[0785] (d) (R)-N-(3-(2-(tert-butylamino)-1-hydroxyethyl)-2-fluorophenyl)isobutyramide

[0786]

[0787] A mixture of (R)-N-(3-(2-bromo-1-hydroxyethyl)-2-fluorophenyl)isobutyramide (240 mg, 0.79 mmol), tert-butylamine (0.83 mL, 7.89 mmol), NaOH (31.6 mg, 0.79 mmol) and iPrOH (0.60 mL, 7.89 mmol) was heated at 65° C. for 3 hours, cooled to room temperature, diluted with EtOAc, washed with water, dried over Na2SO4 and concentrated. The residue was purified by chromatography to give the subtitle compound (180 mg, 0.61 mmol, 77%).

[0788] (e) (R)-1-(3-Amino-2-fluorophenyl)-2-(butylamino)ethan-1-ol dihydrochloride

[0789] A mixture of (R)-N-(3-(2-(tert-butylamino)-1-hydroxyethyl)-2-fluorophenyl)isobutyramide (55 mg, 0.19 mmol) and HCl (1 M, aqueous solution, 1 mL) was heated at 85°C for 3 hours, concentrated and dried to give the title compound (50 mg, 0.17 mmol, 90%). ee = 94%.

[0790] 1 H NMR (400MHz, CD3OD): δ6.94(td,J=7.8,1.0Hz,1H), 6.81(dddd,J=14.7,9.4,7.2,1.8Hz,2H), 5.05(t,J=6.4Hz,1H), 2.78(d,J=6.4Hz,2H), 1.17(s,9H).

[0791] Example 28: (R)-1-(3-amino-2-fluorophenyl)-2-(butylamino)ethan-1-ol dihydrochloride

[0792]

[0793] The title compound was prepared according to the procedure of Example 27 using n-butylamine and MeOH in step (d).

[0794] 1 H NMR (400MHz, D2O): δ7.62(td,J=7.4,6.7,1.7Hz,1H),7.49(td,J=7.8,1.7Hz,1H),7.40(t,J=7.9Hz,1H),5.39(dd,J=9.4,3.6Hz,1H),3.42(dd, J=13.2,3.8Hz,1H),3.36(dd,J=13.2,9.5Hz,1H),3.21–3.12(m,2H),1.72(tt,J=7.9,6.5Hz,2H),1.42(h,J=7.4Hz,2H),0.95(t,J=7.4Hz,3H).

[0795] Example 29: (R)-1-(3-Fluorophenyl)-2-(neopentylamino)ethan-1-ol hydrochloride

[0796]

[0797] A mixture of (R)-2-(3-fluorophenyl)oxirane (60 mg, 0.43 mmol) and neopentylamine (379 mg, 4.34 mmol) was heated at 75°C overnight and concentrated. The residue was dissolved in Et2O (5 mL) and HCl (2M in Et2O, 0.17 mL, 0.35 mmol) was added. The solid was collected and dried to give the title compound (92 mg, 0.35 mmol, 81%).

[0798] 1 H NMR (400MHz, D2O): δ7.50-7.44(m,1H),7.28–7.20(m,2H),7.19–7.12(m,1H),5.16(dd,J=10.0,3.7Hz,1H), 3.38(dd,J=13.2,3.8Hz,1H), 3.32(dd,J=13.2,10.0Hz,1H), 3.05, 3.00(ABq,JAB=12.5Hz,2H), 1.08(s,9H).

[0799] Example 30: (R)-1-(3-Fluorophenyl)-2-((1-(trifluoromethyl)cyclopropyl)amino)ethan-1-ol hydrochloride

[0800]

[0801] A mixture of (R)-2-(3-fluorophenyl)oxirane (60 mg, 0.43 mmol) and 1-trifluoromethyl-1-cyclopropylamine (54 mg, 0.43 mmol) was heated at 75 °C overnight. Another portion of 1-trifluoromethyl-1-cyclopropylamine (54 mg, 0.43 mmol) and DMF (0.33 mL) were added and heating continued. H2O (77 μL, 4.3 mmol) and 1-trifluoromethyl-1-cyclopropylamine (54 mg, 0.43 mmol) were added and heating continued for 3 days, adding a portion of 1-trifluoromethyl-1-cyclopropylamine (54 mg, 0.43 mmol) every day. [The total amount of 1-trifluoromethyl-1-cyclopropylamine was (326 mg, 2.60 mmol)]. The mixture was concentrated and dissolved in Et2O (2 mL). HCl (2M in Et2O, 0.21 mL, 0.43 mmol) was added and the solid was collected and dried to give the title compound (20 mg, 67 μmol, 15%).

[0802] 1 H NMR (400 MHz, CD3OD): δ7.45–7.39 (m, 1H), 7.28–7.20 (m, 2H), 7.12–7.05 (m, 1H), 4.99 (dd, J=10.4, 3.1 Hz, 1H), 3.47 (dd, J=12.7, 3.4 Hz, 1H), 3.33-3.25 (m, 1H, overlapped with CD3OD), 1.65–1.44 (m, 4H).

[0803] Example 31: (R)-1-(3-amino-2,4-difluorophenyl)-2-(tert-butylamino)ethan-1-ol hydrochloride

[0804]

[0805] (a) N-(2,6-difluoro-3-methylphenyl)acetamide

[0806]

[0807] The sub-title compound was prepared according to the procedure in Example 6, step (a) from 2,6-difluoro-3-methylaniline.

[0808] (b) 3-Acetylamino-2,4-difluorobenzoic acid

[0809]

[0810] The sub-title compound was prepared according to the procedure in Example 7, step (b) from N-(2,6-difluoro-3-methylphenyl)acetamide.

[0811] (c) N-(3-(2-chloroacetyl)-2,6-difluorophenyl)acetamide

[0812]

[0813] The mixture of 3-acetylamino-2,4-difluorobenzoic acid (250mg, 1.16mmol) and SOCl2 (2.6mL) was heated at 60°C for 4 hours and then cooled. Toluene was added and the mixture was concentrated. The procedure of adding toluene and then concentrating was repeated three times. The residue was dissolved in CH2Cl2 and trimethylsilyldiazomethane (1.16mL, 2.32mmol) was added dropwise at 0°C. The mixture was allowed to reach room temperature within 18 hours and cooled to 0°C. HCl (4M in dioxane solution, 1.45mL, 5.81mmol) was added dropwise. The mixture was allowed to reach room temperature over 1 hour, diluted with EtOAc and washed with Na2CO3 (saturated aqueous solution), dried over MgSO4 and concentrated. The residue was purified by chromatography to obtain the subtitle compound (198mg, 0.80mmol, 69%).

[0814] (d) (R)-N-(3-(2-chloro-1-hydroxyethyl)-2,6-difluorophenyl)acetamide

[0815]

[0816] RhClCp*[(1S,2S)-p-TsNCH(C6H5)CH(C6H5)NH2] / HCl.Et3N (5.02 mg, 0.0065 mmol) prepared from dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer, (1S,2S)-(+)-N-(4-tosyl)-1,2-diphenylethylenediamine and Et3N as described in WO 2008 / 054155 was added to a DMF mixture (2.7 mL) of N-(3-(2-chloroacetyl)-2,6-difluorophenyl)acetamide (160 mg, 0.65 mmol). Formic acid / Et3N (5:2, 0.90 mL) was added and the mixture was stirred at room temperature for 20 minutes. The mixture was diluted with EtOAc, washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was crystallized from CH2Cl2 / hexane to give the sub-title compound (101 mg, 0.41 mmol, 63%, ee = 97%).

[0817] (e) (R)-N-(3-(2-(tert-butylamino)-1-hydroxyethyl)-2,6-difluorophenyl)acetamide

[0818]

[0819] The sub-title compound was prepared according to the procedure in Example 25, step (d) from (R)-N-(3-(2-chloro-1-hydroxyethyl)-2,6-difluorophenyl)acetamide.

[0820] (f)(R)-1-(3-Amino-2,4-difluorophenyl)-2-(tert-butylamino)ethan-1-ol hydrochloride

[0821]

[0822] NaOH (aqueous solution, 10%, 0.52 mL) was added to a solution of (R)-N-(3-(2-(tert-butylamino)-1-hydroxyethyl)-2,6-difluorophenyl)acetamide (52 mg, 0.18 mmol) in EtOH (0.52 mL), and the mixture was heated at 75 °C for 20 hours. The EtOH was removed in vacuo, and the residue was extracted with CH2Cl2. The combined extracts were washed with water, dried over Na2SO4, filtered and concentrated. The residue was dissolved in Et2O. HCl (2M in Et2O, 0.13 mL, 0.27 mmol) was added. The solid was collected and dried to give the title compound (32 mg, 0.11 mmol, 63%).

[0823] 1 H NMR (400MHz, D2O): δ7.11–7.01(m,2H),5.29–5.15(dd,J=9.6,3.2Hz,1H),3.36–3.23(m,2H),1.40(s,9H).

[0824] Example 32: (R)-2-(tert-butylamino)-1-(3-fluoro-2-methylphenyl)ethan-1-ol

[0825]

[0826] N,N'-bis[(11bS)-3,5-dihydro-3,5-dimethyl-4-oxo-4H-dinaphtho[2,1-d: 1',2'-f][1,3,2]diazaphosphoryl-4-yl]-N,N'-dimethyl-1,5-pentanediamine (15 mg, 18 μmol) and freshly distilled SiCI4 (45.6 μL, 0.40 mmol) were added to CH2Cl2 (0.34 mL) containing 3-fluoro-2-methylbenzaldehyde (50 mg, 0.36 mmol) at -78°C. A solution of tert-butyl isocyanide (49.1 μL, 0.43 mmol) in CH2Cl2 (0.34 mL) was added at -78°C over 4 hours, and the mixture was stirred at -78°C for 2 hours. BH3NH3 (22.3 mg, 0.72 mmol) was added, the cooling bath was removed, and the mixture was stirred at room temperature for 1 hour and diluted with CH2Cl2 (2.5 mL). The mixture was carefully [released gas] added to Na2CO3 (aqueous solution, 10%, 5 mL), stirred at room temperature for 30 minutes, and filtered through diatomaceous earth. The solid was washed with CH2Cl2 (5 mL), and the aqueous phase was collected and extracted with CH2Cl2. The combined organic phase (Na2SO4) was dried and concentrated. The residue was purified by chromatography to obtain the title compound (53 mg, 0.24 mmol, 65%).

[0827] 1 H-NMR (400MHz, CDCl3): δ7.32(d,J=7.6Hz,1H),7.23–7.13(m,1H),6.96–6.91(m,1H),4.79(dd,J=8.8,3. 6Hz, 1H), 2.88 (dd, J=12.4, 3.6Hz, 1H), 2.49 (dd, J=12.0, 8.8Hz, 1H), 2.22 (d, J=1.6Hz, 3H), 1.11 (s, 9H).

[0828] Biological Examples

[0829] L6 myoblasts were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g / l glucose supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 U / ml penicillin, 50 μg / ml streptomycin and 10 mM HEPES. Cells were cultured at 1×10 5 After reaching 90% confluence, the cells were grown in a medium containing 2% FBS for 7 days, where they were then differentiated into myotubes.

[0830] Biological Example 1: Glucose Uptake

[0831] Differentiated L6-myotubes were serum starved overnight in medium containing 0.5% fatty acid-free BSA and induced with agonists (final concentration 1×10 -5 ) stimulation. After 1 hour and 40 minutes, the cells were washed with warm glucose-free medium or PBS, and another portion of agonist was added to the glucose-free medium. After 20 minutes, the cells were exposed to 50 nM 3 H-2-deoxyglucose for 10 minutes, then washed in ice-cold medium without glucose or PBS and lysed in 0,2 M NaOH at 60°C for 1 hour. The cell lysate was mixed with scintillation buffer (Emulsifier Safe, Perkin Elmer) and the radioactivity was detected in a β-counter (Tri-Carb 2800TR, Perkin Elmer). The activity of each compound was compared with that of isoproterenol. If the activity of the compound exceeded 75% of the activity of isoproterenol, the activity was indicated by +++, if it was between 75% and 50%, it was indicated by ++, if it was between 50% and 25%, it was indicated by +, if it was less than 25%, it was indicated by -.

[0832] Biological Example 2: Measurement of intracellular cAMP levels

[0833] Differentiated cells were serum starved overnight and stimulated with 1×10 -5 The cells were stimulated with an agonist for 15 minutes. The medium was then aspirated, and at the end of the reaction, 100 μL of 95% EtOH was added to each well of a 24-well plate, and the cells were placed at -20°C overnight. The EtOH was evaporated, and 500 μL of lysis buffer (1% BSA, 5 mM HEPES, and 0.3% Tween-20, pH 7.4) was added to each well, placed at -80°C for 30 minutes, and then kept at -20°C. Intracellular cAMP levels were detected using the α Screening cAMP Kit (6760635D, PerkinElmer). The activity of each compound was compared with that of isoproterenol. If the activity of the compound exceeded 75% of the activity of isoproterenol, the activity was indicated by +++; if the activity was between 75% and 50%, it was indicated by ++; if the activity was between 50% and 25%, it was indicated by +; if the activity was less than 25%, it was indicated by -.

[0834] Using the assays described in Biological Examples 1 and 2, the following results were obtained.

[0835]

[0836]

Claims

1. A compound of formula IB or a pharmaceutically acceptable salt thereof, wherein: R 1 represents a C optionally substituted by one or more halogen groups 4-12 alkyl; R 2 and R 3 Each independently represents H or C optionally substituted by one or more halogen groups 1-3 alkyl; or R 2 and R 3 may be joined together to form, together with the carbon atoms to which they are attached, a 3- to 6-membered ring, said ring being optionally substituted with one or more groups independently selected from halo and C1 alkyl optionally substituted with one or more halo; Each X independently represents Cl, Br, R a 、-CN、-N3、-N(R b )R c 、-NO2、-ONO2、-OR d 、-S(O) p R e or -S(O) q N(R f )R g ; R a represents C optionally substituted by one or more groups independently selected from G 1-6 alkyl; Each R b , R c , R d , R e , R f and R g independently represents H or C optionally substituted by one or more groups independently selected from G 1-6 alkyl; Or alternatively, R b and R c and / or R f and R g Any of the may be linked together to form a 4- to 6-membered ring together with the nitrogen atom to which it is attached, the ring optionally containing one additional heteroatom, and the ring optionally consisting of C independently selected from halo, optionally substituted with one or more halo 1-3 Alkyl and =O are substituted with one or more groups; G represents halogen, -CN, -N(R a1 )R b1 、-OR c1 、-S(O) p R d1 、-S(O) q N(R e1 )R f1 or =O; Each R a1 , R b1 , R c1 , R d1 , R e1 and R f1 independently represents H or C optionally substituted by one or more halogen groups 1-6 alkyl; Or alternatively, R a1 and R b1 and / or R e1 and R f1 Any of the may be linked together to form a 4- to 6-membered ring together with the nitrogen atom to which it is attached, the ring optionally containing one additional heteroatom, and the ring optionally consisting of C independently selected from halo, optionally substituted with one or more halo 1-3 Alkyl and =O are substituted with one or more groups; m means 2; n represents 0 to 4; The condition is that the sum of m and n is equal to or less than 5; Each p independently represents 0, 1, or 2; and Each q independently represents 1 or 2, The alkyl radical may be straight chain or, when there are a sufficient number of carbon atoms, branched and / or cyclic or partly cyclic.

2. The compound according to claim 1, wherein R 1 represents a C optionally substituted by one or more halogen groups 4-10 Alkyl, for example n-butyl, tert-butyl or 1-methylbutyl.

3. A compound according to any one of the preceding claims, wherein R 2 Indicates H and R 3 Represents H or methyl, such as R 2 and R 3 Each represents H.

4. The compound according to any one of the preceding claims, wherein the F atoms are positioned at the 2-position and the 3-position, or the 3-position and the 4-position, or the 3-position and the 5-position.

5. A compound according to any one of the preceding claims, wherein: a) Each X independently represents Cl, Br, R a 、-CN、-N3、-N(R b )R c , -NO2 or OR d , where R a represents C optionally substituted by one or more F 1-4 Alkyl, R b , R c and R d Each independently represents H or C optionally substituted by one or more F or =O 1-4 Alkyl; or b) Each X independently represents Cl, Br, R a 、-N(R b )R c or -OH, where R a represents C optionally substituted by one or more F 1-2 Alkyl, and R b and R c Each independently represents H or C optionally substituted by =O 1-4 Alkyl; or c) each X independently represents Cl, -NH2, -NHC(O)CH3, -CF3 or -OH.

6. A compound according to any one of the preceding claims, wherein n represents 2, and each X independently represents -NH2, -NHC(O)CH3 or -OH, optionally wherein the X groups are positioned at the 2-position and 3-position, or the 2-position and 4-position or the 3-position and 5-position.

7. A compound according to any one of claims 1 to 5, wherein n represents 1, optionally wherein a) X represents Cl, R a , -NH2, -NHC(O)CH3 or -OH, where R a represents C optionally substituted by one or more F 1-2 Alkyl; or b) X represents -NH2, -NHC(O)CH3 or -OH, Optionally wherein X is positioned at the 3-position, 4-position or 5-position.

8. The compound according to any one of claims 1 to 7, wherein the compound is a compound of formula IC in: a)Y 1 and Y 5 each independently represents H or F; and Y 2 , Y 3 and Y 4 Each independently represents H, F, R a 、-CN、-N(R b )R c or -OH; where R a represents C optionally substituted by one or more F 1-2 Alkyl, and R b and R c Each independently represents H or C optionally substituted by =O 1-4 alkyl, The condition is Y 1 To Y 5 One or both of means F; or b)Y 1 and Y 5 each independently represents H or F; and Y 2 , Y 3 and Y 4 Each independently represents H, F, -N(R b )R c , -CN or -OH, where R b and R c Each independently represents H or C optionally substituted by =O 1-4 alkyl, The condition is Y 2 , Y 3 and Y 4 One or both of means F; or c)Y 1 and Y 5 each independently represents H or F; and Y 2 , Y 3 and Y 4 Each independently represents H, F, -NH2, -NHC(O)CH3 or -OH, The condition is Y 2 , Y 3 and Y 4 One or two of them means F.

9. The compound according to any one of claims 1 to 8, wherein the compound is selected from the group consisting of: (R)-2-(tert-Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol; (R)-2-(Butylamino)-1-(2,3-difluorophenyl)ethan-1-ol; (R)-1-(3-amino-2,4-difluorophenyl)-2-(tert-butylamino)ethan-1-ol and pharmaceutically acceptable salts thereof.

10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, for use in medicine.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers, wherein the compound is present in an enantiomeric excess (ee) of at least 90%.

12. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for use in treating hyperglycemia or a disease characterized by hyperglycemia.

13. The compound or composition for use according to claim 12, wherein: The treatment is for type 2 diabetes, optionally characterized by patients exhibiting severe insulin resistance; or The hyperglycemia or a disease characterized by hyperglycemia is, or is characterized by, the patient exhibiting severe insulin resistance, optionally wherein the disease characterized by hyperglycemia is selected from the group consisting of: Rabson-Mendenhall syndrome, Donohue syndrome, insulin resistance syndrome type A and type B, HAIR-AN (hyperandrogenism, insulin resistance and acanthosis nigricans) syndrome, pseudoacromegaly and lipodystrophy.

14. A combination product comprising: (a) a compound according to any one of claims 1 to 9; as well as (b) one or more other therapeutic agents useful in treating hyperglycemia or a disease characterized by hyperglycemia, Each of components (a) and (b) is optionally formulated in the form of an admixture together with one or more pharmaceutically acceptable adjuvants, diluents or carriers.

15. A kit comprising: (a) a pharmaceutical composition comprising a compound according to any one of claims 1 to 9, and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers, and (b) one or more other therapeutic agents useful in treating hyperglycemia or a disease characterized by hyperglycemia, optionally in admixture with one or more pharmaceutically acceptable adjuvants, diluents or carriers, The components (a) and (b) are each provided in a form suitable for administration in combination with one another.

16. A process for preparing a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, comprising the following steps: (i) making the compound of formula II Where X 1 , X 2 , X 3 , X 4 , R 2 and R 3 As defined in any one of claims 1 to 9, with a compound of formula III H2N-R 1 (III) Where R 1 As defined in any one of claims 1 to 9, optionally reacting in the presence of a suitable solvent; (iia) the compound of formula IV Where m, n, X, R 1 , R 2 and R 3 As defined in any one of claims 1 to 9, and Y 1 Indicates H or PG 1 , where PG 1 is a suitable protecting group, reacting with a suitable reducing agent; (iib) make Y 1 Indicates PG 1 A compound of formula IV, wherein PG 1 is a suitable protecting group (e.g., -C(O)OtBu), in the presence of a suitable catalyst (e.g., a complex between (1S,2S)-(+)-N-(4-tosyl)-1,2-diphenylethylenediamine and [Ru(isopropyltoluene)Cl2]2), in the presence of hydrogen or a suitable hydrogen donor (e.g., formic acid), and optionally in the presence of a base (e.g., Et3N) and in the presence of a suitable solvent (e.g., CH2Cl2); (iii) for compounds wherein at least one X is present and said X represents -OH, deprotecting the compound of formula V under suitable conditions Where m, n, R 1 , R 2 and R 3 As defined in any one of claims 1 to 9, Y 2 Indicates H or PG 2 , where PG 2 represents a suitable protecting group, and PG 3 represents a suitable protecting group; (iv) for compounds wherein at least one X is present and said X represents NH2 or NHC(O)CH3, deprotecting the compound of formula VI under appropriate conditions Where m, n, X, R 1 , R 2 and R 3 As defined in any one of claims 1 to 9, Y 3 Indicates H or PG 5 , where PG 5 represents a suitable protecting group, Y 4 Indicates H, -C(O)CH3 or PG 6 , where PG 6 represents a suitable protecting group, and PG 4 represents a suitable protecting group; or (v) for compounds wherein at least one X is present and said X represents NH2, reducing the compound of formula VII under the synthetic conditions Where m, n, X, R 1 , R 2 and R 3 As defined in any one of claims 1 to 9.